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Resumo 
 
A Polineuropatia Amiloidótica Familiar (PAF) ou amiloidose ATTRV30M é uma doença 
neurodegenerativa, autossómica dominante, causada pela deposição de amilóide 
extracelular de transtirretina mutante (TTRV30M), afectando principalmente o sistema 
nervoso periférico. É caracterizada por uma polineuropatia periférica sensitivo-motora 
progressiva e disfunção autonômica, com manifestações renais, cardíacas e oculares. 
A anemia afecta cerca de 25% dos doentes PAF sintomáticos e é caracterizada por uma 
produção ineficiente de eritropoietina (EPO), independentemente da presença de 
insuficiência renal. Precede por vezes a doença clínica, sugerindo um bloqueio das 
células renais produtoras de EPO. Excluímos anteriormente um efeito inibitório dos 
depósitos de amiloide fibrilar e da TTRV30M em circulação, mas o papel dos agregados 
de TTR não-fibrilares na produção de EPO renal ainda precisava ser explorado. Os 
agregados não-fibrilares ou oligómeros de TTR são citotóxicos, induzindo stress oxidativo 
e a expressão de moléculas relacionadas com a apoptose, e a secreção de citoquinas 
pró-inflamatórias. Alguns destes marcadores também são capazes de inibir a produção 
de EPO. A expressão do gene EPO é regulada ao nível da transcrição pelos factores de 
transcrição HIF, NF-kB e GATA-2. O HIF induz a expressão de EPO em condições de 
hipóxia, por ligação ao enhancer na região 3’, enquanto o GATA-2 e NF-kB inibem a sua 
expressão por ligação ao promotor na região 5’ do gene.  
 
Neste trabalho propusémo-nos explorar os mecanismos moleculares envolvidos no 
bloqueio da produção de EPO na PAF. Utilisando diferentes modelos de cultura de 
células, foi avaliada a influência dos agregados oligoméricos de TTR na viabilidade 
celular, capacidade de diferenciação, expressão do gene da EPO e atividade do seu 
promotor. 
Oligómeros de TTR foram preparados envelhecendo a proteína a pH fisiológico, seguido 
de 5 minutos de agitação. As preparações que continham predominantemente espécies 
de 300 nm foram usadas para os ensaios celulares. 
Uma redução modesta mas estatisticamente significativa da viabilidade celular foi 
induzida pela TTRV30M oligomérica após 24 horas de incubação, independentemente do 
tipo de célula. Concomitantemente com a redução da viabilidade, foi observado um 
aumento da actividade das caspases 3/7 em células Hep3B, SH-SY5Y e RPE expostas 
aos agregados oligoméricos de TTRV30M. Estes resultados estão de acordo com 
estudos anteriores realizados noutros outros tipos de células, e mostram que a apoptose 
está implicada na perda de viabilidade celular. 
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A influência dos agregados oligoméricos sobre a diferenciação celular foi avaliada em 
células progenitoras renais (RPC). Estas têm potencial de diferenciação em podócitos e 
células tubulares renais. Embora os oligómeros de TTRV30M tenham inibido a 
proliferação das RPC, eles não influenciaram a sua capacidade de se diferenciar em 
podócitos funcionalmente maduros, e, portanto, não devem comprometer a regeneração 
dos tecidos. 
A expressão do gene da EPO foi avaliada por PCR em tempo real. Células Hep3B e RPE 
tratadas com TTRV30M oligomérica mostraram uma redução significativa 
(aproximadamente 50%) da expressão de EPO após 24 horas em condições de normóxia 
quando comparado com o controlo e com a exposição à forma tetramérica. Os 
oligómeros de TTR normal também reduziram a expressão de EPO em 22% em células 
Hep3B em normóxia, quando comparada com a com a exposição à forma tetramérica. 
Estes resultados apoiam a nossa hipótese de que espécies oligoméricas citotóxicas 
estarão envolvidas na génese da anemia em doentes com PAF. Além disso, mostrámos 
recentemente que as concentrações de EPO no humor aquoso de olhos com glaucoma 
de doentes não-PAF estão significativamente aumentadas relativamente a olhos sem 
glaucoma. No entanto, em olhos com glaucoma de doentes PAF os níveis de EPO não 
aumentam e mantêm níveis semelhantes aos dos olhos normais, o que mostra a 
incapacidade destes doentes regularem positivamente a produção ocular de EPO. 
Um ensaio repórter foi construído com um fragmento de PCR do promotor da EPO, que 
contém os locais de reconhecimento para GATA-2 e NF-kB, ligados ao gene da luciferase 
para avaliar o papel dos factores de transcrição do promotor. Células Hep3B 
transfectadas e expostas durante 24 horas a TTRV30M oligomérica mostraram uma 
redução significativa da actividade do promotor de EPO (53%) quando comparado com o 
controlo e exposição à forma tetramérica. Estes resultados sugerem que a expressão de 
EPO é inibida pelos agregados oligoméricos de TTRV30M, pelo menos em parte através 
da inibição da actividade do promotor. 
Imunofluorescência e imunohistoquímica foram realizadas para explorar o envolvimento 
do NF-kB e GATA-2 na redução da atividade do promotor da EPO, mas não foram 
observadas diferenças significativas entre as células tratadas com oligómeros ou com a 
forma tetramérica de TTR. 
Em conclusão, os agregados de TTR não-fibrilares podem inibir a produção de EPO e 
contribuir para o aparecimento precoce da anemia nos doentes PAF. Estudos adicionais 
são necessários para elucidar os mecanismos que levam à inibição da EPO, a fim de 
proporcionar marcadores úteis para a avaliação do doente e, eventualmente, novos alvos 
terapêuticos. As células RPE, sendo produtoras quer de TTR como de EPO, poderão 
constituir um bom modelo para estes estudos futuros.  
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Abstract 
 
ATTRV30M amyloidosis or Familial Amyloidotic Polyneuropathy (FAP) is a 
neurodegenerative, autosomal dominant disease, caused by the extracelular amyloid 
deposition of a mutant transthyretin (TTRV30M), affecting particularly the peripheral 
nervous system. It is characterized by progressive sensorimotor peripheral 
polyneuropathy and autonomic dysfunction, and renal, cardiac, and ocular manifestations. 
Anemia affects about 25% of symptomatic FAP patients and courses with low 
erythropoietin (EPO) levels, independently of the presence of renal failure. It sometimes 
precedes clinical disease, suggesting a blockage of kidney’s EPO-producing cells. We 
had previously excluded an inhibitory effect of the amyloid fibril deposits and of circulating 
TTRV30M, but the role of early non-fibrillar TTR aggregates on renal EPO production still 
needed to be explored. Early non-fibrillar TTR aggregates are highly cytotoxic, inducing 
oxidative stress and the expression of apoptosis-related molecules, and secretion of pro-
inflammatory cytokines. Some of these markers are also capable of inhibiting EPO 
production. EPO gene expression is regulated at the transcriptional level by HIF, NF-kB 
and GATA-2 transcription factors. HIF induces EPO expression under hypoxic conditions, 
by binding to the enhancer in the 3’ region, whereas GATA-2 and NF-kB inhibit its 
expression by binding to the promoter in the 5' region of the gene. 
 
In this work, our aim was to explore the molecular mechanisms involved in the blockage of 
EPO production in FAP. Using different cell culture models, we assessed the influence of 
oligomeric TTR aggregates on cell viability, differentiation capacity, EPO gene expression 
and promoter activity.  
TTR oligomers were prepared by aging the protein at physiological pH, followed by 5 
minutes of stirring. Preparations containing species mainly of 300 nm were used for the 
cell culture-based assays.  
A modest but statistically significant reduction in cell viability was induced by oligomeric 
TTRV30M after 24 hours of incubation, independently of the cell type. Concomitantantly 
with the reduction of cell viability, an increase in caspase 3/7 activity was seen in Hep3B, 
SH-SY5Y and RPE  cells exposed to the oligomeric TTRV30M aggregates. These results 
agree with those of previous studies performed with other cell types, and implicate 
apoptosis in the loss of viability. 
The influence of oligomeric aggregates on cell differentiation was evaluated on renal 
progenitor cells (RPC). RPC have self-renewal and multidifferentiation potential into 
podocytes and renal tubular cells. Although TTRV30M oligomers inhibited RPC 
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proliferation, they did not influence their capacity to differentiate into functionally mature 
podocytes, and thus should not compromise tissue regeneration. 
EPO mRNA expression was evaluated by real-time PCR. Hep3B and RPE cells treated 
with oligomeric TTRV30M showed a significant reduction (about 50%) of EPO mRNA 
expression after 24 hours in normoxia, when compared to the control and cells exposed to 
the tetrameric form. Oligomers from normal (wild type) TTR also reduced EPO expression 
by 22% in normoxic Hep3B cells when compared to exposure to the tetrameric form. 
These results support our hypothesis that cytotoxic oligomeric species are involved in the 
genesis of anemia in FAP patients. Besides this evidence, we recently showed that EPO 
concentrations in the aqueous humor of glaucomatous eyes of non-amyloidotic patients 
are significantly increased relatively to normal non-glaucomatous eyes. However, in 
glaucomatous eyes of FAP patients the EPO levels did not increase and maintained 
similar levels to those of control eyes, showing an inability of these patients to upregulate 
ocular EPO production. 
A reporter assay was constructed with a PCR fragment of the EPO promoter, containing 
the recognition sites for GATA-2 and NF-kB linked to the luciferase gene, to evaluate the 
role of transcription factors targeting the promoter. Transfected Hep3B cells exposed for 
24 hours to oligomeric TTRV30M showed a significant reduction of the erythropoietin 
promoter activity (53%) when compared to the control and exposure to the tetrameric 
form. These results suggest that EPO expression is inhibited by oligomeric TTRV30M 
aggregates, at least in part through inhibition of promoter activity.  
Immunofluorescence and immunohistochemistry were performed to explore the 
involvement of NF-kB and GATA-2 in the reduction of EPO promoter activity, but no 
significant differences were observed between the oligomeric TTR-treated and tetrameric 
TTR-treated cells.  
In conclusion, early non-fibrillar TTR aggregates can inhibit EPO production and may 
contribute to the early onset of anemia in these patients. Further studies are needed to 
elucidate the mechanisms that lead to EPO inhibition, in order to provide useful markers 
for patient evaluation, and possibly new targets for therapeutic development. RPE cells, 
as producers of both TTR and EPO, could be a good model for these future studies. 
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1. Amyloid and amyloidosis: short story of its discovery 
 
Amyloid is an insoluble substance that deposits in tissues and organs, mainly in the 
extracellular spaces, leading to progressive organ dysfunction and disease [1-3]. 
Amyloidosis is the group of diseases associated with amyloid deposition [4]. Different 
types of amyloidosis exist, depending on the protein that originates the fibrillar deposits. 
Some proteins undergo conformational changes of their structure due to abnormal 
polymeric assemblies of its subunits, and form amyloid fibrils. Amyloid deposits are 
composed by non-branching fibrils with a β-sheet structure and approximately 10 nm in 
diameter [4]. The fibrils bind the dye Congo red and exhibit green birefringence when the 
Congo red-stained deposits are viewed with polarized light.  
 
 
1.1. Historical review 
The historical review of the discovery of amyloid presented here had as major 
bibliographic sources the detailed accounts of Sipe JD et al. [5] and Kyle RA et al. [6]. 
 
The first description of what we now call amyloidosis may have occured in 1639, when 
Nicolaus Fontanus reported the autopsy of a young man who had an abscess in the liver 
and a large spleen filled with white stones, probably a “sago spleen” amyloidosis. 
In 1838, Matthias Schleiden, a German botanist, used the term amyloid to describe a 
normal amylaceous constituent of plants. Later, in 1854, Rudolph Virchow used the same 
term to describe the corpora amylacea of the nervous system and the substance 
implicated in lardaceous degeneration. He found that, using iodine, these stained blue, 
turning violet upon the subsequent addition of sulfuric acid. This peculiar reaction made 
Virchow consider that these lardaceous deposits were identical to starch.  
In 1859, Carl Friedreich and August Kekule saw that this amyloid “mass” had a proteic 
nature instead of carbohydrate, unlike amylon or cellulose. From this point, amyloid has 
been considered a protein material and, later, as a group of proteins with a propensity to 
undergo conformational changes that result in the formation of fibrils. The name amyloid 
prevailed nonetheless.  
 
Nowadays, it is known that amyloid deposits in tissues have also other non-fibrillar 
components besides the protein, such as proteoglycans (heparan sulfate or chondroitin 
sulfate type), basement membrane constituents (laminin, fibronectin and collagen IV), 
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serum amyloid P component, sulfated glycosaminoglycans (GAG) and apolipoprotein E 
[7-9]. Although the mechanisms by which these components interact with the amyloid 
fibrils are not fully understood, evidence suggests that they may influence the amyloid 
structure to assume a beta pleated sheet rather than an alpha helical conformation [10-
11]. Also, they may contribute to amyloidogenesis by increasing fibril stability, delaying 
their clearance and protecting the amyloid peptide from proteolytic breakdown [12].  
 
In 1922, a new method to detect the presence of amyloid deposits was introduced and is 
still used today. Bennhold injected Congo red, a metachromatic cotton wool dye, in 
patients with amyloid. He noted the disappearance of the dye from the plasma and its 
accumulation in amyloid tissue. Later, in 1927, Divry and Florkin described independently 
a particular property of amyloid stained with Congo red: the apple-green birefringence. 
Amyloid plaques, when stained with Congo red and visualized under polarized light, 
exhibited positive birefringence with respect to the long axis of the deposits, as a result of 
Congo red intercalating into the fibrils. This property of congophilia with apple green 
birefringence was adopted as the main criterion to define the amyloid substance. The 
typical fibrillar morphology is the second criterion.  
 
In 1959, Cohen and Calkins characterized the structure of amyloid [1]. Using electron 
microscopy, they recognized that all types of amyloid shared a similar non-branching 
fibrillar ultrastructure in fixed tissue sections. Later, X-ray diffraction analyses showed that 
amyloid fibrils were ordered with the polypeptide backbone configured as a beta pleated 
sheet and oriented perpendicular to the fibril axis [1-3, 13]. 
In 1967, Shirahama and Cohen saw that the diameter of the isolated amyloid fibril was 
approximately 75-80 Å. A pair of amyloid protofibril about 25-35 Å wide were arranged 
along the long axis of the fibril in a slow twist [14], with an outer band of 4-75 Å and a 
inner band of 8-9 Å [13]. 
 
In 1971, Benditt and Glenner characterized the biochemical heterogeneity of amyloid. 
Using amino acid sequence determination, they saw that each unique protein was 
associated with particular clinical syndromes. They first reported that primary amyloidosis 
was the result of the deposition of fragments of immunoglobulin light chains (AL) either of 
λ- or κ-type [15-16], and that secondary amyloidosis in patients with chronic and recurrent 
acute inflammatory diseases was the result of the deposition of an unknown protein, 
named AA [17-18]. 
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Research on amyloidosis has evolved and nowadays several proteins are known to 
undergo conformational changes causing different amyloid diseases, each with its unique 
clinical features [19].  
 
 
1.2. Classification of the amyloidosis 
A large number of unrelated proteins are known to form amyloid in vivo. A nomenclature 
has been developed to classify the amyloidosis according to the chemical identity of the 
amyloid fibril forming protein. 
 
In 1975, Thomas et al. presented a broad classification of the amyloidosis according to 
the anatomical system that is predominantly affected [20]. This classification has been 
continuously updated and nowadays is managed by the Nomenclature Committee of the 
International Society of Amyloidosis (ISA). According to the last data, there are 31 known 
extracellular fibril proteins in humans, two of which are iatrogenic in nature (table 1) [4].  
 
The nomenclature is based on the amyloid fibril protein, that is designated with a preffix A, 
followed by a suffix that is an abbreviated form of the precursor protein name [4]. The 
amyloidosis syndromes are named after the amyloid fibril protein, e.g. AL amyloidosis, 
wild-type ATTR amyloidosis or hereditary ATTRV30M (p. TTRV50M) amyloidosis.  
Besides this precise molecular classification, amyloidosis are divided into systemic or 
localized and in primary, secondary and inherited amyloidosis. This classification is 
important for clinical practice as the patient’s therapies and prognoses are different [21]. 
 
A list of known amyloid fibril proteins, and their precursors, which form extracellular 
deposits in humans is given on table 1. Some proteins, instead, form intracellular amyloid 
inclusions (table 2).  
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Table 1 - Amyloid fibril proteins and their precursors in human. From Sipe JD et al. [4]. 
Fibril 
protein 
Precursor protein 
Systemic 
and/or 
localized 
Acquired 
or 
hereditary 
Target organs 
AL Immunoglobulin Light Chain S, L A, H All organs except CNS 
AH 
Immunoglobulin Heavy 
Chain 
S, L A All organs except CNS 
AA (Apo) Serum Amyloid A S A All organs except CNS 
ATTR Transthyretin, wild type S A 
Heart mainly in males, ligaments, 
tenosynovium 
 Transthyretin, variants S H PNS, ANS, heart, eye, leptomen 
Aβ2M Β2-Microglobulin, wild-type L A Musculoskeletal system 
 Β2-Microglobulin, variant S H ANS 
AApoAI Apolipoprotein A I, variants S H 
Heart, liver, kidney, PNS, testis, larynx (C 
terminal variants), skin (C terminal variants) 
AApoAII Apolipoprotein A II, variants S H Kidney 
AApoAIV 
Apolipoprotein A IV, wild 
type 
S A Kidney medulla and systemic 
AGel Gelsolin, variants S H PNS, cornea 
ALys Lysozyme, variants S H Kidney 
ALECT2 
Leukocyte Chemotactic 
Factor-2 
S A Kidney, primarily 
AFib Fibrinogen α, variants S H Kidney, primarily 
ACys Cystatin C, variants S H PNS, skin 
ABri ABriPP, variants S H CNS 
ADan* ADanPP, variants L H CNS 
Aβ Aβ precursor, wild-type L A CNS 
 Aβ precursor, variant L H CNS 
APrP Prion protein, wild type L A CJD, fatal insomnia 
 Prion protein, variants L H CJD, GSS syndrome, fatal insomnia 
ACal (Pro)calcitonin L A C-cell thyroid tumors 
AIAPP Islet Amyloid Peptide† L A Islets of Langerhans, Insulinomas 
AANF Atrial Natriuretic Factor L A Cardiac atria 
APro Prolactin L A Pituitary prolactinomas, aging pituitary 
AIns Insulin L A Iatrogenic, local injection 
ASPC‡ Lung Surfactant Protein L A Lung 
AGal7 Galectin 7 L A Skin 
ACor Corneodesmosin L A Cornified epithelia, hair follicle 
AMed Lactadherin L A Senile aortic, media 
AKer Kerato-epithelin L A Cornea, hereditary 
ALac Lactoferrin L A Cornea 
AOAAP 
Odontogenic Ameloblast-
Associated Protein 
L A Odontogenic tumors 
ASem1 Semenogelin 1 L A Vesicula seminalis 
AEnf Enfurvitide L A Iatrogenic 
*ADan is the product of the same gene as ABri.; †Also called amylin.; ‡Not proven by amino acid sequence analysis. 
 
Table 2 - Intracellular inclusions with known biochemical composition, with or without 
amyloid properties. From Sype JD et al. [4]. 
Inclusion name Site Protein nature Examples of associated disease 
Lewy bodies 
Neurons 
intracytoplasmic 
α-synuclein* Parkinson’s disease 
Huntington bodies Neurons intranuclear 
Polyq expanded 
Huntingtin 
Huntington’s disease 
Hirano bodies Neurons Actin Neurodegenerative disorders 
Collins bodies Neurons Neuroserpin Forms of familial presenile dementia 
Not specified 
Neurons, many 
different cells 
Ferritin Form of familial neurodegenerative disorder 
Neurofibrillary 
tangles 
Neurons 
intracytoplasmic 
Tau 
Alzheimer disease, fronto-temporal dementia, 
aging, other cerebral conditions 
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1.3. Primary vs secondary and localized vs systemic amyloidosis 
Amyloidoses may be either idiopathic (primary form) or associated with certain 
inflammatory disorders, immunodeficiency states, endocrinopathies or cancer (secondary 
forms) [22].  
In terms of the location of the amyloid deposits, amyloidosis may be localized or systemic. 
While in localized forms the synthesis of the amyloid precursor and deposition of the fibrils 
occur within the same organ, in systemic forms of amyloidosis, the fibril precursor protein 
is synthesized at a particular site, secreted into circulation and transported to different 
sites [23]. 
 
 
1.4. Diagnosis of amyloidosis 
Amyloid typing is very important to define the treatment, prognosis and course of the 
disease. 
In cases of hereditary amyloidosis, in which a family history exists and a specific mutation 
is considered, genetic testing may be performed. Techniques such as DNA sequencing, 
PCR followed by restriction fragment length polymorphism (RFLP) or high resolution 
melting are commonly used to confirm the diagnosis.  
In cases of acquired amyloidosis or in the absence of a clear family history, the diagnosis 
is usually based on the detection of amyloid deposits in tissue biopsies. Congo red 
staining is performed to detect amyloid deposition, revealed by the presence of the 
characteristic apple-green birefringence (figure 1). When amyloidosis is confirmed, it is 
necessary to type it. Immunohistochemistry on paraffin sections or immunofluorescence of 
frozen sections are techniques routinely performed using a panel of antibodies 
recognizing different amyloid proteins [21, 24]. Immunoelectron microscopy sometimes is 
also used. These antibody based techniques are relatively simple and routinely used in 
pathology laboratories. The results are generally reliable but these techniques also have 
some drawbacks. Some antibodies have low affinity for the misfolded amyloid proteins. 
Also, some mutations may cause loss of epitopes and consequently absence of antibody 
binding [25-26]. 
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Figure 1 – Congo red staining of renal biopsies of ATTR amyloidosis, showing amyloid 
deposition in glomeruli, vasculature, and tubulointerstitium. (A) Congo red staining 
visualized under light microscope; (B) Congo red staining visualized under polarized light, 
showing the apple-green birefringence; (C) Higher magnification of Congo red staining 
visualized under polarized light. From Lobato et al. [27]. 
 
When doubts persist, amyloid fibril proteins can be extracted and amino acid sequence 
analysis performed [28-29]. Proteomic analysis, particularly mass spectrometry, has 
become a useful tool for amyloid typing. Fibrils may be characterized by two-dimensional 
gel electrophoresis (2D-PAGE). Laser microdissection of Congo red positive areas from 
formaline fixed paraffin tissues can also be carried out. Samples are then subjected to 
tandem mass spectrometric analysis to identify the amyloid protein [30]. The recent 
multidimensional protein identification technology (MudPIT) enables a faster identification 
from a peptide mixture of a protein sample. It is a chromatography-based technique that 
couples a triphasic microcapillary column (reversed phase, strong cation exchange and 
reversed phase high-performance liquid chromatography grade materials) with a tandem 
mass spectrometer [31-33]. The peptide mixture is loaded directly onto the triphasic 
microcapillary column which is placed directly in-line with the tandem mass spectrometer. 
Ideally, these methods should complement each other to allow for an unequivocal result.  
 
 
Among all the amyloidogenic proteins, in the following sections attention will be given to a 
systemic and hereditary form of amyloidosis, the ATTR amyloidosis or Familial 
Amyloidotic Polyneuropathy (FAP).   
 A                         B               C 
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2. Familial Amyloidotic Polineuropathy or ATTR amyloidosis  
 
Transthyretin (TTR) is one of the precursor proteins associated with systemic amyloidosis. 
More than 100 mutations have been described for TTR [34-35] and most of them, as well 
as wild type TTR itself, are amyloidogenic. Only about 10 known TTR mutations show no 
propensity to cause amyloidosis.  
Deposition of wild-type TTR is associated with an acquired form of amyloidosis, senile 
systemic amyloidosis (SAA). It affects particularly the heart, leading to cardiac 
complications, and is found mainly in older individuals (>60 years old) and predominantly 
in men. SSA affects approximatly 25% of the population aged more than 80 years [36-37]. 
Amyloidogenic mutations are responsible for hereditary diseases that share some clinical 
manifestations, mainly peripheral and autonomic neuropathy, in familial amyloid 
polyneuropathy (FAP), and less commonly cardiopathy, in familial amyloid cardiopathy. 
 
 
2.1. ATTRV30M amyloidosis 
Historically named Familial Amyloidotic Polyneuropathy type I (FAP-I) or Portuguese type, 
ATTRV30M amyloidosis is a neurodegenerative, autosomal dominant disease, 
characterized by extracelular deposition of mutated TTR (V30M) derived amyloid fibrils 
[38].  
As a matter of simplicity, throughout this document the historical term FAP will be used to 
refer to ATTRV30M amyloidosis. 
 
FAP was first described in 1952 by Corino de Andrade. He reported several patients, the 
first one observed in 1939 in the Santo Antonio Hospital in Oporto, who had a peculiar 
form of peripheral neuropathy with atypical generalized amyloidosis, or paramyloidosis, 
with special involvement of the peripheral nerves [39]. 
In 1978, Costa et al. [40] identified TTR, then known as thyroxin-binding prealbumin, as 
the major constituent of the amyloid deposits in these patients. In 1984, Saraiva et al. 
identified a substitution of methionine for valine at position 30 of the TTR protein as the 
biochemical cause of Portuguese type FAP [38]. Today it is known that Val30Met is the 
most frequent disease associated TTR mutation in Portugal, Sweden, Japan and Italy. 
Although being considered a rare disease (it affects approximately 1:100.000 persons 
worldwide), ATTRV30M amyloidosis is an endemic disease particularly prevalent in the 
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northern regions of Portugal, mainly Póvoa do Varzim, where allele frequency is 
approximately 1:550 [36, 41].  
 
 
2.2. Clinical features of ATTRV30M amyloidosis 
ATTRV30M amyloidosis is a systemic disease characterized by progressive sensorimotor 
peripheral polyneuropathy and autonomic dysfunction, with renal, cardiac, and ocular 
manifestations, among others [42]. Usually symptoms begin in the third to fourth decade 
of life, and develop gradually for 10-20 years, leading to death. Progressive impairment of 
thermal sensitivity and pain are common initial symptoms. The disease progresses with 
lowering of the general state of health, alimentary and sexual dysfunction, malabsorption, 
urinary bladder dysfunction, abnormal glomerular function, cardiac insufficiency and 
vitreous opacities [43-46]. Besides the peripheral nerves, where the amyloid is 
preferentially deposited causing myelin sheet destruction, other organs, such as kidney, 
pancreas, heart, stomach, aorta, skin and eye are affected [47]. Although TTR is 
produced mainly by the liver, this organ is not significantly affected.  
 
 
 
Figure 2 – Schematic representation of clinical manifestations in FAP patients. From Ueda 
et al. [47]. 
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In this work, more attention will be given to renal and ocular complications, and in 
particular, to the expression of erythropoietin by these two organs in FAP patients. This 
subject will be discussed later in further detail. 
 
 
2.3. Therapeutic strategies for ATTR amyloidosis 
Advances are being made in the treatment of ATTR amyloidosis and many therapeutic 
strategies have been proposed, which act on 3 important checkpoints: 
A) Blocking the synthesis of TTR protein  
B) Stabilization of the TTR tetramer to inhibit TTR disaggregation 
C) Disruption and promotion of TTR amyloid fibrils clearance  
 
 
 
Figure 3 – Schematic representation of the mechanism proposed for TTR 
amyloidogenesis and some therapeutic strategies for FAP. From Hanna 2014 [48]. 
 
 Block TTR synthesis 
Liver transplantation 
Since 1990, liver transplantation (LT) has become a therapeutic option for FAP patients, 
as it eliminates more than 95% of the abnormal protein from circulation [49-50]. 
Approximately 120 LTs are performed worldwide each year [http://www.fapwtr.org]. When 
LT is performed in the early stage of the disease, it can prolong survival, halt the 
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progression of clinical manifestations and even improve autonomic and, to a lesser extent, 
peripheral nerve function [51-53].  
A strategy to manage the scarcity of healthy livers for transplantation was adopted with 
sequential or domino LT, in which FAP patients receive a healthy liver from a deceased 
donor and their liver is transplanted into patients with malignant or end-stage liver 
diseases. As FAP only manifests after the 2nd or 3rd decade of life, it would be expected 
that a FAP liver recipient would not manifest the disease. However, some recipients of 
FAP livers started developing TTR amyloid deposits and disease symptoms less than 10 
years after the surgery [54-56].  
LT has important drawbacks: it is extremely expensive; transplanted patients must be 
treated with immunosuppressants lifelong; non-symptomatic carriers of TTR mutations as 
well as FAP patients in advanced stage do not undergo liver transplantation. Although 
circulating mutant TTR is virtually eliminated, there are reports of continuing formation and 
deposition of fibrils from wild-type TTR, causing cardiomyopathy and/or neuropathy after 
liver transplantation, findings that seem similar to those observed in senile systemic 
amyloidosis (SSA) [57-60]. Also, LT does not prevent the production of mutant TTR in the 
cerebrospinal fluid and in the eyes, where the mutant protein is still secreted by choroid 
plexus and retinal pigmented epithelium, respectively. Ocular and central nervous system 
(CNS) problems may occur, highlighting the importance of non-neural dysfunction in post-
transplant patient management [61-62].  
 
Gene therapy 
Antisense oligonucleotides (ASO) and small interfering RNAs (siRNAs) are effective gene-
silencing tools that could be promising for FAP gene therapy [48]. Blocking hepatocyte 
synthesis of TTR would prevent the production of both mutant and wild type TTR, which 
could be a potential treatment for both hereditary and acquired ATTR amyloidosis. Phase 
3 studies are currently ongoing for some ASOs and siRNAs [48, 63]. 
Antisense oligonucleotides (ASOs) are synthetic single stranded oligomers designed to 
be complementary to a specific region in a target mRNA, promoting its degradation, thus 
preventing production of the associated protein [64]. The drug ISIS-TTR Rx from Isis 
Pharmaceuticals (Carlsbad, CA) targets the TTR mRNA preventing the production of both 
mutant and wild-type TTR protein. This ASO suppresses TTR mRNA levels in the liver 
and in the choroid plexus of the brain [65-67].  
siRNAs are sequence-specific post-transcriptional gene silencing molecules. Patisiran, 
also known as ALN-TTR02, from Alnylam Pharmaceuticals (Cambridge, MA) is a lipid 
nanoparticle formulation of a synthetic siRNA that selectively silences both mutant and 
wild-type TTR gene expression, both in vitro and in vivo [65, 68-69].  
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 Stabilize the TTR tetramer 
TTR binding of its natural ligand thyroxine (T4) stabilizes the tetramer against dissociation. 
The same strategy has been tested using small molecules that could bind to the TTR T4 
pocket to kinetically stabilize the native tetramer and avoid the conformational changes 
that lead to amyloid fibril formation [70].  
Diflunisal, a non-steroidal anti-inflammatory drug (NSAID) with a molecular structure 
similar to T4, binds to the T4 binding sites on the TTR tetramer, stabilizing it and 
preventing acid mediated fibril formation in vitro [71-74], as well as in serum of 
amyloidosis patients, without adverse effects [73, 75]. A 2 years long clinical trial showed 
that Diflunisal treated patients had substantially less polyneuropathy progression 
compared to placebo [76]. 
Tafamidis (Vyndaqel) or Fx-1006A, like Diflunisal, is a small molecule that selectively 
binds to the T4 binding site and stabilizes the TTR tetramer [77], but without NSAID 
activity. FAP patients treated with Tafamadis have shown a significant benefit relatively to 
an untreated control group. Tafamidis stabilizes plasmatic TTRV30M protein, slowing 
disease progression [77-78]. It became the first pharmacological treatment for FAP 
patients to be approved in Europe [79]. 
 
 Clearance of TTR amyloid fibrils 
The presence of other compounds in the amyloid fibrils besides the core protein led 
several groups to investigate the possibility to target them as a strategy to promote 
clearance of amyloid fibrils, regardless of the amyloid type. 
Doxycycline, an antibiotic, was shown to be an effective fibril disrupter, disaggregating 
TTR amyloid fibris in mice transgenic for human TTRV30M, promoting amyloid deposit 
reabsorption [80-81].  
TUDCA (Tauroursodeoxycholic acid), a biliary acid with antioxidant and antiapoptotic 
activities, significantly decreased the amount of TTR aggregates, as well as oxidative and 
apoptotic biomarkers associated with disease, also in a transgenic mouse model [82-83].  
A trial of a combination of TUDCA with Doxycyline was conducted in aged FAP mice [82] 
and was more effective than either doxydoxycycline or TUDCA alone. It significantly 
lowered TTR deposition and associated tissue markers and also disaggregated mature 
amyloid deposits in the gastrointestinal tract.  
EGCG (Epigallocatechin-3-gallate), the predominant polyphenol in green tea, has shown 
in vitro the capacity to both inhibit fibril formation and also disrupt amyloid fibrils by 
converting existing fibrils into non-fibril conformers [84-86]. 
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Anti-SAP antibodies could contribute to clear amyloid fibrils. Serum Amyloid P 
component (SAP) is a plasma glycoprotein universally associated with amyloid fibrils. 
Encouraging data was seen in animal models as well as in a heterogeneous group of 
amyloid patients treated with anti-SAP antibodies [87-88]. 
 
 
2.4. Diagnosis 
As for other amyloidosis, the diagnosis is based on histological examination, genetic 
testing or mass spectrometry. ATTRV30M amyloidosis results from a single adenine for 
guanine nucleotide change in exon 2 [89], which creates a restriction site for the enzyme 
NsiI. This facilitates the molecular diagnosis, which can be performed by PCR followed by 
RFLP, or by real-time PCR (rtPCR) genotyping based on melting curve analysis. Also, 
amino acid substitution results in a known mass shift in the protein molecular weight [90], 
making it possible to use mass spectrometry analysis [91-93]. This is particularly useful in 
the setting of liver transplantation. 
Recently, our group described a case report of a FAP patient who underwent orthotopic 
liver transplantation from a cadaveric donor [94]. Continuing deterioration in this patient 
raised the suspicion, confirmed in 2012, that the liver donor was also a TTRV30M carrier, 
so retransplantation was proposed and carried out. Immunoprecipitation of TTR from the 
serum of the cadaveric donor, followed by mass spectrometry analysis [95] enabled to 
confirm the absence of TTRV30M, concluding that this second time the transplanted liver 
was FAP free. 
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3. Renal and ocular complications in ATTRV30M 
Amyloidosis: its association with low erythropoietin 
production 
 
TTRV30M amyloid deposits are commonly found both in the kidney as well as in the eye 
of FAP patients and give rise, respectively, to renal and ocular problems in these patients.  
 
 
3.1. Renal complications: nephrotic syndrome and anemia 
In ATTRV30M amyloidosis, renal amyloid deposition occurs mainly in the glomerular 
mesangium and medulla, with a typical involvement of the distal convoluted tubule and 
Henle's loop, which may lead to tubular atrophy and loss of tubular function [27]. Clinical 
nephropathy manifests initially as a microalbuminuria and then progresses to proteinuria 
and renal failure. In FAP patients, nephrotic syndrome may be associated with anemia 
with decreased levels of EPO, sometimes below the lower limit of the normal range, 
without associated iron deficit [96]. These patients do not respond to iron therapy but 
treatment with recombinant EPO is effective [97].  
According to World Health Organization criteria, anemia is defined as a concentration of 
hemoglobin (Hb) <13 g / dL in men and <12 g / dL in women [98]. 
 
 
3.1.1. Defective EPO production by the kidney in ATTRV30M amyloidosis 
Anemia has been described in ATTRV30M amyloidosis patients: 
 Moderate normocytic normochromic anemia was observed in 39% of the Swedish 
FAP patients [99];  
 macrocytic and hypochromic anemia was reported in a group of 35 Japanese FAP 
patients [100].  
 normocytic and normochromic anemia was present in 25% from a total of 165 
symptomatic FAP patients, even in the presence of normal renal function, and is 
associated with a defective renal production of EPO, revealed by serum levels lower 
than expected [96].  
 
A deficit of EPO in Portuguese FAP patients is an early event that was observed 
independently of the presence of renal failure and sometimes preceding clinical disease 
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[96]. Serum EPO levels were, on average, 11.2+6.7 mU/mL, lower than the expected 
levels (35+13.9 mU/ml) for the degree of anemia, while iron stores, B12 vitamin, and 
serum folate levels were normal in these patients. Normalization of iron status was 
insufficient for the correction of anemia, but therapy with low doses of recombinant EPO 
was effective [97], excluding a defective response of the bone marrow as a cause of 
anemia in these patients. 
Circulating EPO is mainly produced by the kidney in the adult. The observed low EPO 
production suggests a defect of the EPO-producing cells, which could be related to either 
the presence of amyloid deposits in the renal interstitium or with other factors, such as 
circulating TTRV30M itself.  
The amyloid deposits present in renal biopsies were found to have no correlation with 
serum EPO levels, independently of the neuropathy score, the amount of amyloid 
deposition or the renal clinical manifestations [101].  
Anemia in liver transplant recipients is usually due to the side-effects of 
immunosuppressive therapies, iron deficiency, renal failure and post-transplant 
lymphoproliferative disorders [102]. A study performed in cirrhotic patients showed that 
anemia affected 85% of these patients before liver transplantation. After liver 
transplantation, anemia decreased to 18% [103]. In contrast, in FAP patients the 
prevalence of anemia increased even after liver transplantation, and defective 
endogenous EPO production persisted [104], excluding an inhibitory effect of the 
circulating TTRV30M on the EPO-producing cells.  
Pro-inflammatory cytokines can inhibit EPO gene expression, contributing to the anemia 
of chronic disease [105]. In ATTRV30M amyloidosis, inflammation is observed, 
particularly with up-regulation of TNF-α, macrophage colony-stimulating factor and IL-1β 
[106-107], which could explain the low EPO levels in these patients. However, Beirão et 
al. analyzed 24 FAP patients and found no evidence of systemic inflammation, as no 
significant differences were found on interleukin-6, transferrin saturation, ferritin and 
hepcidin-25 [108]. 
 
 
3.2. Ocular complications: vitreous opacities and glaucoma 
ATTRV30M amyloidosis is associated with several ocular manifestations such as lacrimal 
dysfunction, pupillary disturbances, changes in the conjunctiva, presbyopia [109], dry eye 
[110], vitreous opacities, which may occur before any other systemic manifestation of the 
disease [111], and, most seriously, severe glaucoma. Liver transplantation in FAP patients 
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proved unable to halt the progression of these ocular manifestations, probably due to the 
continued production of the mutated TTR by the retinal pigment epithelial cells [62].  
A retrospective study of 477 symptomatic FAP patients was performed by Beirão et al. 
which showed that these patients have amyloid deposits in the iris, in the anterior lens 
capsule and in the vitreous. Vitrectomy with complete removal of the vitreous is usually 
carried out, but when the vitrectomy is incomplete new amyloid deposits are formed due 
to continuing deposition in the remaining vitreous [112].  
Glaucoma can develop rapidly in FAP patients and, if not treated, may lead to blindness. 
A correlation was found between vitrectomy and glaucoma, with vitrectomy favoring the 
onset or worsening of glaucoma [113].  
 
3.2.1. Defective EPO production by the eye in ATTRV30M amyloidosis 
Glaucoma causes an increase in intraocular pressure, which leads to activation of 
neuroprotective mechanisms. Studies have reported upregulation of EPO expression and 
an increased intravitreal EPO concentration in some ocular disorders [114], which may 
reflect the cytoprotective function of EPO in response to hypoxia, ischemia, and 
inflammation [115]. Recently, our group found that EPO concentrations in the aqueous 
humor of glaucomatous eyes of non-FAP patients are significantly increased relatively to 
normal non-glaucomatous eyes, probably as a protective role. However, in glaucomatous 
eyes of FAP patients the EPO levels did not increase and maintained similar levels to 
those of control eyes [116]. These results show an inability of FAP patients to upregulate 
EPO production both systemically by the kidney and locally by the pigmented epithelium.  
Glaucoma is the second leading cause of blindness worldwide [117]. Vascular 
abnormalities and altered blood flow at the optic nerve head may lead to local hypoxia, 
accelerating neuronal cell death in patients. The hypoxia inducible factor 1 (HIF-1) is 
thought to be involved in the pathology of glaucoma, as increased activation of HIF-1 was 
found in glaucomatous eyes and localization of this protein was correlated with regions of 
visual field defects [118]. HIF is one of the main regulators of EPO expression, by 
inducing it in situations of hypoxia. In glaucoma, as a consequence of HIF activation, EPO 
levels are strongly elevated, probably as a cytoprotective response.   
 
The mechanisms responsible for the low expression of EPO in FAP patients, whether as a 
response to anemia, or as a response to ocular damage, as in the case of glaucoma, 
remain unexplained. What is certain is that these patients do not increase EPO levels in 
response to stimuli to which a non-PAF patient would respond with an increase in 
expression of this cytokine/hormone.  
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4. Erythropoietin 
 
Erythropoietin (EPO) is a hormone essential for red blood cell production. A moderate 
reduction in hemoglobin concentration is sufficient to increase EPO mRNA expression, 
which occurs within minutes of the onset of hypoxia, reaching a maximum after 6 hours 
[119-121]. Daily, it stimulates proliferation and differentiation of about 2x1011 erythroid 
progenitor cells in the bone marrow, contributing to the control of blood oxygen capacity 
throughout the body [122].  
EPO is an endocrine, paracrine and autocrine hormone. Besides its hematopoietic 
function, EPO has been shown to be a cytoprotective hormone. Among other effects, EPO 
antagonizes the activity of pro-inflammatory cytokines, has neuroprotective functions and 
promotes healing through stimulation of angiogenesis and capillary growth [123]. 
 
 
4.1. Erythropoietin structure 
Human EPO is a glycoprotein of 30.4 kDa encoded by 5 exons located in chromosome 7 
as a single copy gene. Translation of the EPO gene results in a polypeptide chain of 193 
amino acids that is cleaved posttranslationaly, both at the N- and C-terminal sites. The 
secreted protein has 165 amino acids [124].  
About 40% of the molecular weight of EPO is due to carbohydrate chains. EPO has 4 
glycosilated side chains that are important to its biological function by conferring thermal 
and structural stability, protection against free radicals, increased plasma half-life and 
selectivity [122, 125-126]. EPO has 4 α-helices and 2 dissulfide bonds with 3 asparagine 
N-glycosilation and 1 serine O-glycosilation sites. The sialic acid residues attached to the 
4 carbohydrate chains are particularly important for the maintenance of in vivo half-life and 
biological activity [126-127].  
 
 
4.2. Sites of erythropoietin production 
During fetal life EPO is produced by the liver, whereas in the adult it is mainly produced by 
the kidney [128]. The molecular mechanisms underlying this switch are poorly understood, 
but are thought to involve the transcription factor GATA-4 [129], which is highly expressed 
by hepatocytes only in the fetal liver. Its inhibition leads to a dramatic reduction in Epo 
gene transcription in Hep3B cells.  
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Many efforts were done to identify the renal EPO-producing cells. Evidence has been 
provided for different locales including: renal glomeruli [130], peritubular interstitial or 
endothelial cells in anemic mouse [131-132], peritubular interstitial cells in hypoxic 
monkey [133], tubular epithelial cells [134-135] and proximal tubular cells [136-137]. In 
2010, our group identified distal tubular cells and cortical collecting tubules as the major 
site of EPO production in normal adult human kidneys from patients with ATTRV30M 
amyloidosis with or without anemia [138]. In 2013 Bussolati et al. identified a subset of 
renal CD133(+)/CD73(+) progenitor cells isolated from the human renal inner medulla, 
with a mesenchymal phenotype, as a possible source of EPO under hypoxic conditions, 
via the prolyl hydroxylase-HIF-2α axis [139]. CD133+ progenitors have been identified 
along the renal nephron [140] which overlaps with the described localization of EPO-
producing cells in different segments of the human nephron by in situ hybridization 
studies. In addition, Nagai et al. demonstrated recently in mice that EPO mRNA 
expression occurs in proximal convoluted tubules (PCTs), distal convoluted tubules 
(DCTs) and cortical collecting ducts (CCDs) under normoxic conditions and in peritubular 
cells in severe hypoxia [141]. These dissimilarities may result from inter-species 
differences. Additionally, it is likely that EPO production by different populations of renal 
cells depend on the varying hypoxic conditions used in the different experimental models.  
 
Apart from the kidney, EPO production has been found also in the brain [142], retina, lung, 
spleen, bone marrow, in the male and female reproductive organs [143-144], placenta 
[145] and also in numerous cancer cells [124].  
 
Although EPO is mainly produced by the kidney in the adult, an adequate renal EPO-
producing cell line is not available. So, most of the present knowledge of the O2 sensing 
mechanism that controls EPO expression has been based on in vitro studies using the 
human hepatoma cell lines Hep3B and HepG2, described in 1987 by Goldberg et al. as a 
constitutive and inducible EPO producer, in an oxygen-dependent manner [146]. 
 
 
4.3. Erythropoietin functions: hematopoiesis and cellular protection 
Recognition that the EPO receptor (EPOR) was expressed in several cells other than the 
erythroid progenitor cells led to the discovery of the extra-hematopoietic functions of EPO. 
EPO is a member of the cytokine type I superfamily [147], and is both an endocrine, 
paracrine and autocrine hormone.  
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4.3.1. Hematopoietic function 
EPO major function is to promote survival of EPO-dependent colony-forming unit-erythroid 
(CFU-E) cells and erythroblasts. EPO synthesis is regulated at the mRNA level, through 
mechanisms sensitive to oxygen concentration. In response to hypoxia, EPO production 
increases in a few hours [148], and acts on the erythroid progenitor cells in the bone 
marrow stimulating their proliferation and differentiation.  
EPO binds to the erythropoietin receptor (EpoR) homodimer, which is located on the 
surface of erythroid progenitor cells, and triggers a conformational change that brings its 
intracellular domains into close proximity, resulting in transphosphorylation and activation 
of Janus kinase 2 (JAK2) [124]. Downstream cascades are initiated via different signaling 
pathways including signal transducer and activator of transcription 5 (STAT5), 
phosphoinositide 3-kinase (PI3K)/AKT, and mitogen-activated protein kinase (MAPK) via 
adapter proteins like Src homology containing protein (SHC). These transcription factors 
translocate to the nucleus and drive or inactivate transcription of genes involved mainly in 
survival and prevention of apoptosis of erythroid progenitors [149].  
 
EpoR is expressed at the highest level on erythroid progenitor cells and plays a critical 
role in the regulation of red blood cell production by EPO. However, expression of the 
EpoR beyond hematopoietic cells raised the possibility that EPO activity associated with 
survival, proliferation and differentiation of erythroid cells might not be restricted to 
erythropoiesis. 
EPO can also signal via a heterodimeric receptor composed of an EpoR monomer chain 
and CD131, the β common cytokine receptor [150]. This heterodimeric complex is found 
in nonerythroid cells and is thought to be involved in nonerythroid effects of EPO [124]. 
 
4.3.2. Extra-hematopoietic functions: cellular protection 
Recent findings have demonstrated that EPO has also a cytoprotective function.  
EPO has direct effects on immune cells, endothelial cells, bone marrow stromal cells, as 
well as cells of the heart, brain, reproductive system, gastrointestinal tract, muscle, kidney, 
pancreas, and nervous system [150-152]. The nonerythropoietic functions of EPO include: 
promoting cardiac and central nervous system development, blocking cell death in stroke 
models, improving learning and memory, regulating angiogenesis, confer protection in 
ischemia/reperfusion injury of the kidney, liver, heart and myocardial infarction and 
modulate responses to injuries such as cerebral ischemia, cardiac infarction and retina 
degeneration [124, 150]. In vitro recombinant EPO stimulates the proliferation, 
mobilization, and differentiation of endothelial progenitor and precursor cells and also 
enhances endothelial cell viability and survival by blocking apoptosis [124]. EPO also 
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protects against diabetes in mouse models, through direct JAK2 signaling in pancreatic 
cells, resulting in cell survival and proliferation, reduced inflammation, and increased 
angiogenesis in the islets [150]. EPO may act on the regulation of metabolism and obesity 
and have potential benefits in the treatment of neurologic diseases, mood symptoms and 
depression. 
In the immune system, EPO responds to tissue injury caused by pathogens, trauma and 
hypoxia in order to maintain a balance between inflammation and anti-inflammation [153]. 
To limit an uncontrolled inflammatory response, inflammation or hypoxia can trigger EPO 
expression to inhibit proinflammatory cytokine production (TNF-α and interleukin 6), to 
increase expression of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO), and 
block inducible nitric oxide synthase (iNOS) expression [149, 154], to inhibit macrophage 
activity by blocking NF-κB p65 signaling pathway [155], and delimit the volume of injury by 
counteracting apoptosis [153].  
 
 
 
Figure 4 – Multifaceted effects and targets of EPO. (A) EPO targets many cell types and 
tissues, including erythroid cells and their progenitors, tumor cells, and a variety of other 
nonerythroid cells and tissues. (B) EPO signals in erythroid cells via EPOR-EPOR 
homodimers and in nonerythroid cells via EPOR-CD131 heterodimers. From Broxmeyer 
2013 [150]. 
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4.4. Use of recombinant EPO to treat anemia 
A variety of EPO derived recombinant forms of erythroid stimulating agents (ESAs) have 
been used in research and in clinical practice since 1986 [156]. ESAs are used to treat 
anemia in several fields such as end-stage renal disease, malignancies associated with 
chemotherapy, AIDS and surgical interventions [157]. ESAs are able to increase red blood 
cell count, hemoglobin and hematocrit levels, decreasing the need for red blood cell 
transfusion and possibly improving quality of life [156]. 
Several ESAs have been developed, with the rationale of cost saving and prolonged 
survival in circulation. ‘Epoetin’ has an amino acid sequence identical to the endogenous 
human EPO. Darbepoetin alfa has a longer survival in circulation and Mircera (methoxy 
polyethylene glycol-epoetin beta) has the longest half-life (130-140 h on IV injection) 
[157].  
However, side effects of EPO treatment have emerged: potentially life-threatening cardiac 
complications such as stroke, increase in arterial blood pressure and possibly 
hypertension, increase the incidence of thromboembolism [157], especially with higher 
doses and rapid increase in hemoglobin levels. 
 
 
4.5. Regulation of the erythropoietin gene 
EPO gene expression is activated in response to many forms of stress, but hypoxia is the 
most important stimulus [158]. When O2 concentration drops, EPO gene expression is 
activated and an exponential increase in EPO protein plasma levels occurs [159].  
Regulation of EPO gene expression occurs at different levels: transcription, mRNA 
stabilization and at the translational level by an upstream open reading frame [160-163]. 
At the transcriptional level, Hypoxia Inducible Factor (HIF), GATA-2 and NF-kB 
transcription factors are the main known regulators of EPO gene expression [164-167]. 
HIF induces EPO expression under hypoxic conditions, while GATA-2 and NF-kB 
suppress EPO promoter activity when activated by the pro-inflammatory cytokines IL-1 
and TNF-α [168]. 
 
4.5.1. Hypoxia inducible factor (HIF) 
The EPO gene has a cis-acting hypoxia response element (HRE) located in the enhancer 
at the 3’-flanking region. Under hypoxic conditions, the hypoxia-inducible factor HIF binds 
to the HRE and induces EPO expression [169, 170]. 
HIF is a heterodimeric transcription factor composed by an O2-sensitive α-subunit and a 
constitutively expressed β-subunit, and is expressed in all tissues of many species [171]. 
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Three α chain isoforms of HIF were identified (HIF-1α, HIF-2α and HIF-3α). HIF-1α and 
HIF-2α have similar regulatory mechanisms and are both involved in O2 delivery and in 
cellular adaptation to hypoxia. However, several studies point to differences in the 
expression and cellular distribution pattern, which may be indicative of different functions. 
Whereas HIF-1α is expressed in all nucleated cells, the expression of HIF-2α is restricted 
to specific cell types, including vascular endothelial cells, renal interstitial cells, 
hepatocytes, cardiomyocytes, glial cells and astrocytes [172]. Rosenberger et al. found, 
inducing hypoxia in rats, that regardless of the type of stimulus, the cell populations 
expressing HIF-1α and HIF-2α in the kidney are different. HIF-1α was predominantly 
expressed in cells of the proximal and collecting tubules, and HIF-2α was expressed 
predominantly in the peritubular interstitial cells and some glomerular cells [173]. Because 
HIF-2α accumulates in peritubular cells and these have been described as the site of EPO 
production, it was suggested that HIF-2α would be the regulator of EPO expression in the 
kidney. However, several studies show that both HIF-1α and HIF-2α contribute to the 
regulation of EPO, although differentially, according to the cell type.  
 
The production and activation of HIF is regulated at the level of the α chain, which 
increases exponentially as O2 concentration declines. Two oxygen-dependent 
mechanisms are involved in this regulation. Under normoxia, in the first mechanism, two 
conserved proline residues located in the oxygen-dependent degradation domain (ODDD) 
undergo hydroxylation by the action of prolyl-hydroxylases (PHDs) and this allows the 
ubiquitination of the α chain by the complex von Hippel-Lindau protein (pVHL)/E3-ubiquitin 
ligase, and subsequent degradation by the proteasome [124]. In the second mechanism, 
an asparagine residue (Asn803) is hydroxylated by HIF inhibition factor (FIH1) and HIF 
activity is suppressed by preventing the binding of the transcription coactivator p300/CBP 
(CREB-binding protein), which acts to increase the expression of their target genes. The 
PHDs and FIH1 use oxygen as co-substrate. So, under hypoxia, a decrease in the oxygen 
tension results in inhibition of both PHDs and FIH1. The α-chain dimerizes with the β 
chain, the HIF complex is stabilized and, after recruitment of co-activator p300/CBP, binds 
to the HRE of HIF target genes [124]. Additionally, HIF cooperates with hepatocyte 
nuclear factor 4 (HNF-4), which binds to the 3′ EPO hypoxia enhancer region [124]. 
Recently, it was shown that HIF-2α may regulate erythropoiesis by a mechanism 
independent of PHD enzymes. HIF-2α is acetylated during hypoxia and deacetylated by 
Sirtuin 1, a nicotinamide adenine dinucleotide (NAD)+-dependent protein deacetylase, 
which increases HIF-2-dependent EPO synthesis, linking cellular redox and energy state 
to systemic hypoxia responses. Sirtuin 1-deficient mice produced significantly lower 
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amounts of fetal liver Epo mRNA, and as adults less EPO in response to severe hypoxia 
[171].  
 
The hydroxylation of HIFα can be carried out by three prolyl-hydroxylases (PHD1, PHD2 
and PHD3), among which PHD2 plays the predominant role at most sites. The prolyl 
hydroxylase inhibitor FG-4497 was used in rats to induce HIF-dependent erythropoietin 
transcription, and in fact EPO mRNA expression was strongly induced and co-localized 
with HIF-2α [174]. It is likely that the PHDs are the primary O2 sensors in the control of 
EPO production. Chemical compounds, such as the α-ketoglutarate, Roxadustat 
(ASP1517/FG-4592) and dimethyloxalylglycine (DMOG) can inhibit PHDs, providing a 
potential oral therapy for stimulating erythropoiesis in patients with chronic kidney disease. 
A phase 3 clinical trial using Roxadustat is currently ongoing to evaluate its safety and 
efficacy, when compared to epoetin alfa, for the treatment of anemia in patients with 
chronic kidney disease on dialysis [175-176]. It has the advantage of offering an oral 
treatment and circunventing the need for multiple injections. DMOG was used in this work 
to mimick hypoxia conditions and to stimulate EPO expression.  
 
4.5.2. GATA-2 and NF-kB 
Besides HIF, EPO expression is also regulated by GATA-2 and NF-kB at the level of the 
promoter. There is little information about the mechanisms by which these transcription 
factors regulate the EPO promoter, but it is known that both act by inhibiting the promoter 
activity.   
The EPO promoter is suppressed by GATA-2 in normoxia and GATA-2 levels decrease in 
hypoxia [160]. The activation of GATA-2, with consequent inhibition of EPO gene 
expression, may be related to a pro-inflammatory stimulus, to increased production of 
H2O2 and to the presence of L-NG-monomethylarginine (L-NMMA). Exogenous addiction 
or endogenous production of H2O2 enhance the expression of GATA-2 and its binding 
activity, suppressing the activity of the EPO promoter and thus inhibiting EPO gene 
expression [177-179]. 
L-NMMA, an endogenous nitric oxide synthase (NOS) inhibitor that is markedly elevated 
in uremic patients, increases GATA-2 mRNA expression and its binding to the EPO 
promoter, both in normoxia and hypoxia. EPO promoter activity is inhibited by GATA-2 
causing a decrease in EPO expression and protein production [179-180]. L-NMMA did not 
alter the binding activity of HIF-1, HNF-4 or NF-kB in these experiments.  
EPO production may be also suppressed by the pro-inflammatory cytokines IL-1 and TNF-
α, which activate GATA-2 and NF-kB and may contribute to the anemia of chronic disease 
in part by suppressing EPO production [168]. NF-kB binds to the EPO promoter in a 
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region close to the binding site for GATA-2, and inhibits its activity. Souma T et al. 
showed, with a mouse model of adult-onset anaemia caused by erythropoietin deficiency 
(ISAM), that inflammatory injury activated NF-kB inducing a pathological phenotypic 
switch of the renal EPO-producing cells (REP) to myofibroblasts [181].  
 
4.5.3. ATF3 
The activating transcription factor ATF3, although not classically described as a regulator 
of EPO expression, is also involved in the activation of the EPO promoter in response to 
the platelet-derived growth factor (PDGF) signaling system [182]. ATF3 is rapidly induced 
upon exposure of cells to stress signals [183]. Elevated expression of PDGF has been 
observed in RPE cells after retinal detachments or retinal laser treatment in murine model 
systems [184], in in vitro wounded human RPE cell cultures [185] and in epi-retinal 
membranes isolated from proliferative vitreoretinopathy and proliferative diabetic 
retinopathy patients [186]. 
 
Other transcription factors, such as retinoic X receptor-α (RXR-α), Wilms tumor 
suppressor (WT1), SMAD3 and Sp1, may contribute to the regulation of EPO expression. 
RXR-α contributes to EPO activation through interaction with EPO enhancer in the fetal 
liver during early erythropoiesis [187]. WT1 directly up-regulates EPO expression in 
hepatocytes, through binding to the EPO promoter [188]. SMAD3 binding to the 3' EPO 
enhancer, and Sp1 binding to the EPO promoter region also cooperate with HIF, HNF4 
and p300 in EPO gene transcription in hypoxia [189]. Together these factors act to 
stabilize the multifactorial complex interacting with EPO promoter and enhancer to 
regulate EPO expression. 
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5. The transthyretin protein  
 
Transthyretin (TTR) is a plasma protein involved in the transport of retinol, in a complex 
with retinol binding protein (RBP), and of the thyroxine (T4) hormone [190-191], hence its 
name: trans (transport) thy (thyroxine) and retin (RBP). Formerly it was named prealbumin 
because it migrates just slightly ahead (anodal) of albumin in serum protein 
electrophoresis. 
Liver and choroid plexus are the most abundant sites of TTR synthesis in humans. Liver 
produces circulating TTR that is secreted to the plasma where it reaches a concentration 
of approximately 200-250 mg/L (ranging from 3-8 µM) [192-194]. Choroid plexus, in turn, 
has the highest concentration of TTR mRNA in the body as TTR accounts for 12% of all 
proteins synthesized [195]. The protein produced by the choroid plexus is secreted into 
the cerebrospinal fluid (CSF), where it reaches a concentration ranging from 5 to 20 mg/L 
(0,09-0,4 µM) [193]. In CSF, 80% of T4 is bound to TTR whereas only 15% of T4 is bound 
to TTR in the serum [196-197].  
TTR is also found in the eye, as it is produced by the pigment epithelium (ciliar and retinal) 
[198], and in less extent in alpha-cells of pancreatic islets [199], yolk sac [200], placenta 
[201], and intestine [202].  
 
 
5.1. Transthyretin structure 
TTR is encoded by a single copy gene with 4 exons located at chromosome 18. Exon 1 
codes mainly for a signal peptide of 20 aminoacids that is cleaved before secretion of 
mature TTR [203-204]. 
Structurally, TTR is a tetrameric protein with 4 identical subunits, each with 127 
aminoacids and a molecular mass of approximately 14 kDa [205]. Each monomer 
contains 8 β-sheet strands (A-H) and a short helix between strands E and F [206]. The 4 
monomers associate non-covalently to form the tetrameric protein, which has a molecular 
mass of approximately 55 kDa.  
Association of two dimers is subjacent to the tetrameric structure. The strength of the 
interactions between monomers (resulting in a dimer) and between dimers (forming a 
tetramer) suggests that the dimer rather than the monomer or tetramer is the most stable 
unit of the TTR structure [207].  
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Figure 5 – Structure of human transthyretin monomer (A), dimer (B) and tetramer (C). 
From Protein Data Bank, PDB ID:s 1F41, 2PAB 
 
 
The tetramer has 2 identical binding sites for T4 in a central channel and 4 surface binding 
sites for the complex RBP/vitamin A. However, only one binding site is occupied by T4 
under physiological conditions due to negative co-operativity [208]. Also, only one RBP 
molecule can bind to TTR due to steric hindrance [209].  
 
 
5.2. TTR function 
TTR main function is the transport of T4 and of retinol-binding protein (RBP), which in turn 
transports vitamin A, both in the plasma and in the CSF. However, TTR is not likely to be 
essential for life or developmentbecause no abnormalities are found in mice that have had 
the transthyretin gene inactivated [210].  
There are studies that suggest that the complex TTR-T4 is endocytosed and internalised. 
This phenomenon was observed in hepatomas, primary hepatocytes and renal cells and 
involves an endocytic multi-ligand receptor of the LDL receptor family, megalin (LRP2) 
[211-213].  
TTR also has a protease activity [214]. A fraction of plasma TTR circulates bound to 
Apolipoprotein A-1 (ApoA1) and acts as a protease, as it is able to cleave the carboxyl-
terminal domain, after a phenylalanine residue, of ApoA1 [214]. TTR can also cleave full 
length β-amyloid to a smaller fragment, and play a protective role in AD [215]. 
A     B  
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5.3. Models of amyloidogenesis 
Various mechanisms have been proposed to explain amyloidogenesis. 
 
Mutations in several proteins lead to structural changes that promote unfolding and 
predispose for the formation of fibers, resulting in hereditary amyloidosis syndromes. In 
the case of TTR, several mutations alter the thermodynamics and kinetics of dissociation 
of the tetramer and favor the formation of intermediates that self assemble into amyloid 
fibers [216]. 
For example, the V30M mutation confers a moderate instability to the tetramer, while 
L55P is the most unstable and pathogenic variant. However, the presence of mutations is 
not essential for amyloidogenesis to be triggered. Examples are some localized 
amyloidoses, and again using the example of TTR, senile systemic amyloidosis is caused 
by deposition of amyloid fibers from wild-type TTR. Many factors can trigger 
destabilization of the protein structure: heat shock, oxidative stress or chemical 
modifications, alterations of intracellular macromolecular crowding, presence of suitable 
surfaces, absence of stabilizing ligands, impairment of intracellular quality control of 
protein folding, pH changes and others [217]. 
Most in vitro studies regarding the formation of amyloid fibers are based on lowering the 
pH, suggesting that mildly acidic pH (present for example in lysosomes) can induce  
rearrangement of the tetramer structure and dissociation into partially denatured 
monomeric amyloidogenic intermediates, that are then joined again to form amyloid fibrils 
[23]. However, it has been shown that normal TTR, as well as the variants V30M, L55P 
and the non-amyloidogenic T119M dissociate into monomeric species at physiological pH 
and ionic strength [30] and that the most unstable variants (V30M- and L55P-TTR) exist in 
a complex equilibrium between monomers, tetramers and aggregates of higher molecular 
weight [30]. 
Nowadays, it is thought that the critical step for amyloidogenesis is the destabilization of 
the structure and the formation of non-native intermediate species that have the ability to 
self-associate. 
 
These intermediate species seem to play an important role both in the formation of 
amyloid fibrils as in the mechanisms of toxicity subjacent to amyloid disease. 
Depending on conditions, during the process of amyloidogenesis different types of 
species can be formed: amorphous aggregates, soluble oligomers or amyloid fibrils [218-
221], and the process rarely results in a homogeneous product. Usually, heterogeneous 
mixtures containing several species of aggregates (amyloid fibrils, amorphous aggregates 
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or soluble oligomers) are observed. Amorphous aggregates are formed faster than 
oligomers or fibrils and usually result from partially unfolded proteins that precipitate out of 
solution with no special conformational prerequisite to occur. Soluble oligomers are 
formed more slowly and remain in solution even after high-speed centrifugation, indicating 
that are not insoluble fibrillar or aggregated species. Fibrils are the slowest formed 
species and require special conditions to be formed. 
 
 
Figure 6 – A schematic representation of the protein self-association process, highlighting 
the three major products of the aggregation reaction: amorphous aggregates, soluble 
oligomers (spheroidal and annular) and amyloid fibrils. From Uversky 2010 [222]. 
 
 
The three main mechanisms proposed for TTR amyloidogenesis are: template-dependent, 
template-independent and proteolisis mechanisms [218]. 
 
Template-dependent 
The aggregation of the protein results from a nucleation-polymerization process where 
addition of the monomers is thermodynamically unfavorable until a nuclear-core is formed 
[223]. Rather, the polymerization stage is thermodynamically favorable. The critic nuclear 
core is the oligomer with the minimum size cable of starting the elongation process [224]. 
In the case of TTR there is no evidence that amyloidogenesis proceeds this way [225]. 
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Template-independent 
Aggregation is a process that begins with the monomeric protein and ends with the 
formation of aggregates. In between, a number of steps occur, including the formation of 
different oligomers [222]. The model accepted for TTR is based on a conformational 
change, in which altered monomers are the building blocks for amyloid fibril formation 
[224, 226]. 
 
Proteolysis hypothesis 
In some types of amyloidosis, the protein precursor is a subproduct of partial proteolysis 
(eg, reactive systemic amyloidosis (AA), immunoglobulin amyloidosis (AL), Alzheimer's 
disease (Aβ), gelsolin, cystatin C and apoA-I amyloidoses. In the case of TTR, C-terminal 
fragments are found, in addition to the full-length protein, in amyloid deposits of SSA and 
FAP patients [227]. However, these fragments are not always present, and their role is still 
controversial. 
 
Recently, Pires et al. described the existence of distinct annular oligomeric intermediates 
formed during both the assembly and disassembly pathways of TTR protofibrils induced at 
acidic pH [228]. They suggested that annular oligomers undergo morphological transitions 
into spheroid oligomers and protofibrils, which can be reversed to annular oligomers at 
physiological pH. 
 
In the TTR assembly pathway, aggregation was induced by acidification. Within the first 
hours, the sample was mostly populated by monomeric particles as a result of tetramer 
dissociation. After a few hours, annular oligomers with circular shape and octameric 
symmetry, as well as more compact spheroid oligomers were observed. The spacing of 
each subunit of the annular oligomers was consistent with the dimensions of a single wild-
type TTR monomer. These annular oligomers may associate laterally and form spheroid 
oligomers and short protofibrils. After 7 days of incubation, only protofibrils and a small 
population of monomers/dimers remained. So, the annular oligomers seem to be a 
transient intermediate along the protofibrillogenesis pathway.  
 
The disassembly pathway occurred when the TTR protofibrils that were formed in acidic 
conditions were exposed to physiological buffer. After 15 minutes exposed to 
physiological pH, there was dissociation of the protofibrils into annular oligomers, which 
were different from those observed during TTR assembly but may still serve as assembly 
blocks for another form of amyloid aggregation. 
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Figure 7 – Model of TTR protofibril assembly and disassembly. From Pires et al. [228]. 
 
 
So, in the protofibrillogenesis model proposed by Pires et al. the native TTR undergoes 
structural transitions upon acidification, and the tetramers dissociate into amyloidogenic 
monomers and, in smaller quantities, dimmers, from which annular oligomers with 
octameric symmetry assemble. A single annular oligomer may serve as a scaffold for the 
continuous addition of subunits up to the formation of an annular doublet. Spheroid 
oligomers coalesce in a dynamic equilibrium with the growing protofibrils which are 
abundant in the first week of incubation. Upon adjusting of pH to neutral, protofibril 
structure quickly reorganizes, and dissociation into an annular oligomeric species quite 
distinct from that seen in the assembly pathway proceeds in a time scale of minutes. 
 
The annular oligomeric species are probably toxic, as it has been seen that oligomers 
containing up to eight TTR monomers, but not more, are cytotoxic [229]. 
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5.4. Methods to induce the formation of oligomeric species in vitro 
In vitro amyloidogenesis and formation of oligomeric species can be achieved by several 
methodologies, as long as the conditions that promote fibril formation are established. It is 
a difficult endeavour because variability exists between protein batchs and has been 
plagued by poor reproducibility of experiments both within and among laboratories [230]. 
Factors such as the purity of the protein sample, the ion-pairing agent used in the protein 
purification process, for example HCl and trifluoroacetic acid (TFA) buffers, the existence 
of pre-formed aggregates that can behave as fibril seeds and lead to accelerated amyloid 
formation, can contribute to this variability by affecting the kinetics of aggregation.  
To promote fibril formation, the sample is incubated under a variety of different solution 
conditions (pH, temperature, and ionic strength). The most common methods are: 
 incubating the protein with stirring at room temperature for 7 days [231] 
 using low pH treatment of purified protein: diluting the protein in sodium acetate 
buffer at pH 3.6 and incubating at 37ºC [228]; diluting in acetate buffer, KCl and 
EDTA, pH varying from 4.8 to 6.0 [229, 232-233], followed by incubation at 37°C for 
a maximum of 7 days [229]  
  incubating the protein for 48 h at room temperature in trifluoroethanol and sodium 
acetate, pH 5.5 [234]. 
 also, different concentrations of the protein and pH solutions, using either acetate or 
citrate buffer, may be used [235].  
 
The choice of the method may depend on the protein involved or on the previous 
experience of the laboratory. 
 
 
5.5. Cytotoxicity induced by oligomeric and pre-fibrilar TTR species 
Mature amyloid fibrils were for long considered the responsible species for the pathogenic 
features of amyloid diseases, as they were the material commonly found in the 
pathological deposits. However, in later years, evidence has accumulated that the soluble 
oligomers and pre-fibrillar assemblies grown from the amyloidogenic proteins are the main 
or even the sole cytotoxic species [229, 236-239]. Most of these evidences come from cell 
culture-based experiments, as these soluble species have not been well characterized in 
vivo. Other circunstancial evidences, such as the fact that clinical manifestations of 
amyloidosis-related neurodegenerative diseases often precede detectable accumulation 
of the fibrillar protein aggregates, lend support to this theory. So, soluble oligomers are 
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considered very important players both in protein aggregation and in the related 
cytotoxicity.  
 
The existence of early non-fibrillar TTR aggregates in pre-symptomatic FAP patients is 
supported by studies conducted by Sousa et al. [107]. The presence of these putatively 
cytotoxic aggregates is associated with the expression of markers of oxidative stress, and 
induction of apoptosis related molecules and pro-inflammatory cytokines [107], processes 
that may be common to the toxicity of prefibrillar amyloid protein aggregates in all 
amyloidotic diseases [234]. 
The mechanisms that mediate the cytotoxicity of oligomeric TTR aggregates are not yet 
fully understood. However, several pathways, including ER stress, oxidative stress and 
inflammation, have been implicated. 
 
5.5.1. ER stress response in FAP 
A connection between the endoplasmic reticulum (ER) stress response and FAP was 
demonstrated by Teixeira et al. [240]. Increased levels of the ER-resident chaperone BiP, 
a member of the heat-shock protein 70 family, were found both in human biopsies of FAP 
patients as well as in TTR transgenic mouse model [240]. It was also shown that 
extracellular TTR oligomers can induce BiP expression and activation of eIF2α in cell 
culture, involving the mobilization of Ca2+ from the ER to the cytosol.  
An N-glycosylated TTR fraction was identified in plasma of carriers of the V30M mutation, 
which was undetectable in plasma of normal individuals. This glycosylated TTR was 
secreted, escaping ER-associated degradation (ERAD) [241]. 
 
5.5.2. Disruption of biological membranes 
Amyloidogenic species could be toxic by their capacity to interact and permeabilize the 
biological membranes, through mechanisms such as detergent, carpeting effects or pore 
formation [242]. Studies in vitro suggest that the TTR-mediated calcium permeability may 
be driven by binding of the misfolded protein directly to lipids of the plasma membrane, 
and that toxicity is correlated with increased membrane binding affinity, destabilisation of 
cell membrane fluidity and subsequent decrease in cell viability [243]. 
 
5.5.2. Apoptosis 
Activation of caspase-3 was described in sciatic nerves of asymptomatic FAP individuals 
in which non-fibrillar TTR aggregates were observed [107], as well as in cells treated with 
pre-fibrilar aggregates [107]. The death receptor Fas as well as caspase-8 were found to 
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be up-regulated in tissues from animal models for FAP with non-fibrillar TTR deposition, 
as well as in salivary glands from FAP patients [244].  
The TTRV30M protein itself may induce apoptosis and autophagy concomitant with the 
accumulation of reactive oxygen species (ROS) [245]. 
Nunes et al. found that TTRV30M decreases endothelial survival by inducing apoptosis 
[246]. In this study it was also shown that TTR could regulate angiogenesis, as endothelial 
cells seem to acquire different molecular identities when exposed to either wild-type TTR 
or TTRV30M proteins.  
 
5.5.3. Inflammation 
The pro-inflammatory cytokines TNF-α, IL-1β and M-CSF (macrophage colony-stimulating 
factor) were found to be up-regulated in nerves from FAP patients [106-107]. IL-1β, in 
particular, was investigated as a possible therapeutic target in an FAP mouse model. 
Treatment with Anakinra, an IL-1 antagonist, prevented TTR extracellular deposition in 
sciatic nerve, protecting unmyelinated nerve fibers from aggregate-induced degeneration 
[247]. Moreover, Anakinra administration significantly inhibited apoptosis and nitrative 
stress, highlighting the relevance of the IL-1 signaling pathway in the pathophysiology of 
FAP. On the other hand, up-regulation of the anti-inflammatory cytokine IL-10 in axons 
and Schwann cells of FAP nerves, and its correlation with the presence of TTR amyloid 
deposits was also observed, suggesting a balance between pro- and anti-inflammatory 
mechanisms in FAP [248]. 
 
5.5.4. Oxidative stress 
Oxidative stress markers were found to be increased in axons of FAP patients even at 
pre-symptomatic stages of disease [107], as well as the levels of iNOS [244, 249] and of 
3-NT (3-nitrotyrosine), a marker of protein nitration, in FAP nerves, suggesting that 
deposited TTR was subjected to nitration [106]. 
 
5.5.5. The receptor for advanced glycation end products (RAGE) 
It has been postulated that TTR aggregates can bind to the receptor for advanced 
glycation end-products (RAGE), which is highly expressed at the surface of different cell 
types in amyloid deposition sites, and activate extracellular signal-regulated kinase (ERK) 
cascades, leading to downstream increased nuclear transcription factor kB (NF-kB) 
activity, and activation of caspases [250-251]. The inflammatory cascades are 
consequently activated by NF-kB and in turn will promote NF-kB activation [252-253].   
Several evidences suggest that both AGE and RAGE may have a common role in the 
progression of TTR amyloidosis, as amyloid proteins may directly bind to RAGE and 
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activate signaling pathways that result in cellular perturbations [251, 254]. However, 
conflicting results exist regarding the fact that the cytotoxic effects exerted by the 
oligomeric TTR may be triggered by activation of NF-kappaB or apoptosis [254]. 
 
 
5.6. EPO deficiency and TTRV30M aggregate toxicity: common mechanisms 
As previously stated, TTR aggregates can bind to RAGE, which is highly expressed at the 
surface of different cell types in amyloid deposition sites, and activate ERK cascades, 
leading to downstream increased NF-kB activity, and activation of caspases. These 
mediators, as well as others involved in oxidative stress and apoptosis may influence EPO 
production. So, downstream events precipitated by the deposition of cytotoxic oligomeric 
species may be involved in the inhibition of EPO expression. Hypoxia Inducible Factor 
(HIF), GATA-2 and NF-kB are the main known regulators of EPO gene expression. HIF 
induces EPO expression under hypoxic conditions, while GATA-2 and NF-kB transcription 
factors suppress EPO promoter activity when up-regulated or activated by the pro-
inflammatory cytokines IL-1 and TNF-α [168]. 
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6. Renal Progenitor Cells 
 
After acute renal damage, either ischemic or toxic, the kidney is able to regenerate and, in 
most cases, to completely recover its function and the integrity of the tubular epithelium. 
Recent studies have identified the renal cells that are responsible for this regenerative 
response. In man, a population of stem/progenitor cells, selectively localized at the urinary 
pole of the Bowman's capsule [255] was identified. It is characterized by the expression of 
the markers CD24 and CD133, as well as by expression of transcription factors 
characteristic of multipotent stem cells such as Oct-4 and BMI-1. The discovery of these 
progenitor cells in a region of the nephron which is contiguous with both the tubular 
structures and with podocytes [255], suggests that they represent common progenitors 
and can replace damaged cells in both structures. These cells are distributed along the 
Bowman's capsule and generate new podocytes, progressively migrating from the urinary 
pole to the vascular pole, where complete differentiation into podocyes take place [256-
257]. Studies in mice suffering from glomerulosclerosis showed that these cells have the 
ability to integrate the mature structure, reducing proteinuria and improving the chronic 
renal damage [256]. When injected in mice with acute renal failure (SCID), the progenitors 
have the ability to regenerate different portions of the nephron and reduce renal damage, 
both morphological and functionally [255]. 
 
Cells expressing the surface markers CD133 and CD24, as well as vimentin, were also 
identified as tubular progenitors, close to the proximal tubular epithelium of the adult 
kidney [258]. Furthermore, in biopsies from patients with acute tubular necrosis, these 
CD133+ vimentin+ cells proliferate, so it may be assumed that they represent a population 
of progenitor cells [258]. In agreement with these observations, Sallustio and colleagues 
have confirmed the existence of CD133+CD24+ cells in the adult human kidney scattered 
along the tubular epithelium, both in proximal and distal tubular segments, and found that 
these cells have a gene expression profile not statistically different from that of the 
CD133+CD24+ cells of the glomerulus [259]. 
 
Studies from Angelotti and colleagues [260] went further and demonstrated that progenitor 
cells from the Bowman's capsule express a different marker VCAM1 (Vascular Cell 
Adhesion Molecule 1) or CD106, which is absent in the tubular stem cells, allowing to 
distinguish and separate them between CD133+CD24+CD106+ or CD133+CD24+CD106-
. These CD106- cells are located in specific segments of the nephron: the proximal and 
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distal convoluted tubules. In turn, CD133+CD24+ cells were not identified at the level of 
the Henle’s loop or of the collecting duct. 
 
The progenitors from the Bowman’s capsule exhibited a high proliferative potential and 
the ability to differentiate and acquire both the phenotype of podocytes and of tubular 
cells, while the tubular CD133+CD24+CD106- cells showed a much lower proliferative 
capacity and a phenotype already commited to tubular differentiation. Both populations, 
however, showed a capacity for greater resistance to toxic agents than already 
differentiated renal tubular cells. Moreover, both the glomerular CD133+CD24+CD106+ 
cells and tubular CD133+CD24+CD106- cells, if inoculated into mice with acute tubular 
injury, were integrated at tubular level and showed the ability to reduce kidney damage 
from both a morphologically and functionally point of view [260]. This suggests that both 
cell populations can potentially participate in the regeneration of cells in the adult human 
kidney. 
 
The identification of the factors that regulate cell growth and differentiation properties of 
tubular progenitors opens important perspectives in terms of regenerative medicine. In the 
case of amyloidosis it is important to know if the misfolded protein influences the 
differentiation capacity of the renal progenitor cells. The development of potential 
therapeutic agents to prevent and treat tubular damage may depend on this knowledge. 
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Aims 
 
The results obtained over the last few years by our group have shown that erythropoietin 
(EPO) production is reduced in ATTRV30M amyloidosis (FAP) patients, leading to anemia 
at an early stage of the disease. Our previous studies have excluded a direct effect of 
either the presence of amyloid fibril deposits or of soluble circulating TTRV30M on EPO 
expression. As oligomeric TTR aggregates are now generally considered as the most 
cytotoxic species in ATTR amyloidosis, and suspected mediators of toxicity are likely to 
influence EPO expression, we decided to evaluate the effect of oligomeric TTRV30M 
aggregates on EPO expression. 
Complementary, an assessement of oligomeric TTRV30M aggregate toxicity in the 
differentiation potential of the renal progenitor cells (RPC) CD133+CD24+ was carried out. 
These cells have the capacity to differentiate either as podocytes or as tubular structures, 
and are able to integrate in vivo different portions of the nephron, contributing to its 
regenerative potential. 
 
So, in outline, the main objectives of this study are: 
 To assess the cytotoxicity of oligomeric TTRV30M aggregates in vitro, using 
different target cell lines (Hep3B (human hepatocellular carcinoma), SH-SY5Y 
(human neuroblastoma cell line), HEK293T (human embryonic kidney cell line), 
and RPE (human retinal pigment epithelial cells) 
 To evaluate the effect of oligomeric TTRV30M aggregates on EPO gene 
expression in Hep3B cells, and the role of known regulatory regions of the EPO 
gene. 
 Establish a primary human EPO-producing cell line from retinal pigment epithelium 
(RPE) and evaluate the effect of TTR aggregates on these cells. 
 To evaluate the effect of TTR aggregates on the viability and regenerative 
potential of renal progenitor cells (RPC) CD133+CD24+ 
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1. Cell culture models and human renal biopsies 
 
In this work we used both immortalized and primary cell lines in experimental models.  
 
Immortalized cell lines: 
Hep3B (human hepatocellular carcinoma) 
SH-SY5Y (human neuroblastoma cell line) 
HEK293T (human embryonic kidney 293 cell line) 
 
Primary cell lines: 
RPC (human renal progenitor cells) CD133+CD24+ 
RPE (human retinal pigment epithelial cells) 
 
Hep3B cells were kindly offered by Dra. Sandra Alves (Department of Human Genetics, 
INSA, Portugal).  
 
SH-SY5Y and HEK293T were kindly offered by Prof. Paola Romagnani’s group 
(Excellence Centre for Research, Transfer and High Education (DENOTHE), University of 
Florence, Italy).  
 
RPC cells were isolated from the glomeruli of adult human kidney, as described by 
Sagrinati et al. [255], by the collaborators of Prof. Paola Romagnani.  
 
RPE cells were isolated from the choroid of an eye of an adult human cadaveric donor 
from Centro Hospitalar do Porto, in the setting of a project approved by the institutional 
ethics committee. The procedure for RPE isolation was adapted from Engelmann et al. 
[261] and Chung et al. [262]. Briefly, the RPE/choroid complex was placed in RPMI 
supplemented with 10% FBS, 10 µg/mL gentamicin, 0,5 mg/mL colagenase I and 0,5 
mg/mL colagenase IV, was triturated with a bistoury and incubated for 4 hours at 37ºC. 
After incubation, the cells and media were collected and centrifuged for 5 minutes at 1400 
rpm. The pelleted cells were washed with PBS, centrifuged and resuspended in RPMI 
supplemented with 10% fetal bovine serum (FBS) and 20 µg/mL gentamicin. The 
pigmented cells were counted using a neubauer chamber and plated at a density of 
350.000 cells in a 25 cm2 culture flask.   
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The RPC cells were maintained in EGM-MV (Cambrex Bio Science) supplemented with 
10% FBS (Hyclone). All the other cell types were maintained in RPMI 1640 supplemented 
with GlutaMax (Invitrogen, CA, USA) and 10% FBS (Invitrogen). All cells were incubated 
at 37ºC in a 5% CO2 atmosphere.  
 
 
Human renal biopsies  
In this study, 14 human formalin-fixed and paraffin embedded renal biopsies from renal 
cadaveric donors and ATTRV30M amyloidosis patients were used. Biopsies were 
provided by the Pathology Department of Santo António Hospital and informed consent 
for research use was obtained. Three renal biopsies from cadaveric donors whose kidney 
was successfully transplanted were selected as controls. No donor clinical data was 
available due to the anonymity rules imposed in organ collection procedures. Between 
1995 and 2001, every FAP patient considered for liver transplantation was submitted to 
renal biopsy. Eleven biopsies from FAP patients were randomly selected, taking into 
consideration as inclusion criteria the absence of anemia, scarse deposition of amyloid in 
the kidney and normal renal function. FAP patients were on average 38 ±7 years old (29 – 
56), with 4.5 ± 2.1 years (2 – 12) of symptomatic disease, and serum Hb of 13.2 ± 1.6 (10 
– 16.2) g/dl. 
 
 
 
2. Expression and purification of recombinant human TTRV30M  
 
The in vitro studies conducted in this work evaluated the effect of TTR aggregates in the 
cellular models described in section 1 of this chapter. To do so, it was of crucial 
importance to obtain TTR preparations of very good quality, and free of any kind of 
contamination, such as endotoxin, to ensure that the effects observed with cells exposed 
to these preparations for several days were only due to their presence. To this end, we 
produced under stringent conditions recombinant human TTRV30M, using an E. coli 
expression system. As a control for some experiments we also used a sample of 
commercially available wild-type TTR (Sigma). 
 
Recombinant Human TTRV30M was produced using a strain of chloramphenicol (cam) 
resistant BL21-RIL E. coli transformed with the made-to-order synthetic vector 
pJexpress401:34985–TTRV30M_v2_opt (pJT, DNA2.0 Inc.). Transformants were 
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selected for resistance to cam and kanamycin (kan), and the presence of the correct 
vector was confirmed.  
Expression and purification of the recombinant protein was optimised. Briefly, a colony of 
BL21-RIL/TTRV30M clone (pJT) was grown overnight in 3 mL of LB medium with 50 
μg/mL kan and 16 μg/mL cam at 37ºC and 220 rpm. The pre-culture was inoculated in 
600 mL TB medium with the same antibiotics and grown for 4 h at 37ºC and 250 rpm. The 
expression of the protein was induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG), for 4 h at 30ºC and 250 rpm. The cells were collected by centrifugation and the 
pellet was stored at -20ºC.  
To extract the protein, the pellet was dissolved in lysis buffer (50 mM Tris.HCl, pH 7.6, 
200 mM NaCl, 10 mM imidazole) and treated with 100 μg/mL lysozyme, on ice for 30 min. 
The mixture was sonicated 3 x 30 s in pulse mode (0,5 s “on” and 0,5 s “off”) and 
centrifuged. The supernatant was filtered, first through a 0,45 µm membrane and then 
through a 0,2 µm membrane, and applied to a prepacked Ni2+ sepharose high 
performance column (HisTrap HP, GE Heathcare) equilibrated in lysis buffer, an 
immobilized metal ion affinity chromatography (IMAC). After washing the column with 7 
volumes of lysis buffer, a linear gradient of 10 - 400 mM imidazole was applied to elute the 
His-tagged protein. The elution peak fractions were pooled and their content verified by 
SDS-PAGE with Coomassie Blue or silver staining. The TTR containing fractions were 
dialysed overnight at 4ºC against H2O, quantified by absorbance spectroscopy at 280 nm 
(Thermo Scientific NanoDropTM 1000 Spectrophotometer), using the extinction coefficient 
of wild-type TTR (wt-TTR), ε280 = 7.76 x 104 M-1 [263], and stored at -20ºC.  
To remove the histidine tag, the chromatography product was cleaved with recombinant 
TEV protease, produced in our laboratory using the S219V TEV mutant, encoded in the 
pRK793 plasmid. This vector overproduces the catalytic domain of TEV protease in the 
form of an MBP fusion protein that cleaves itself in vivo to yield a TEV protease catalytic 
domain with an N-terminal His-tag and a C-terminal polyarginine tag, and was a kind gift 
from David Waugh (Addgene plasmid # 8827) [264]. It was expressed in BL21(DE3)-RIL 
cells, and TEV S219V purified by IMAC with a Ni2+ sepharose high performance column, 
as described for TTRV30M. The cleavage reaction was performed at room temperature 
for at least 4 h in 50 mM Tris.HCl pH 7.6, 0.5 mM EDTA, 1 mM DTT, using a ratio of 1 mg 
of TEV for 10 mg of TTRV30M. Following digestion, the reaction was dialysed against 50 
mM Tris.HCl pH 7.6, 200 mM NaCl and TEV protease was removed via its own poly 
histidine tag by IMAC. These TTRV30M fractions were pooled, concentrated and buffer 
exchanged with 50 mM Tris.HCl pH 7.6, by ultrafiltration, using a centrifugal filter device 
with a molecular weight cut off of 10 kDa. 
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An ion exchange chromatography was performed to further purify the recombinant 
TTRV30M. The protein was applied to a Q-Sepharose FF column equilibrated in 50 mM 
Tris.HCl pH 7.6. A linear gradient of 0 - 500 mM NaCl was applied to elute the TTR. 
Finally, the TTR containing fractions were concentrated by ultrafiltration and applied to a 
gel filtration Sephacryl S-200 column equilibrated with 10 mM phosphate buffer pH 7, 100 
mM KCl and 1 mM EDTA. The appropriate fractions were pooled and concentrated by 
ultrafiltration.  
Purified soluble TTRV30M was detoxified using ActiClean Etox (Sterogene). The protein 
was eluted with PBS (Invitrogen), concentrated to a final concentration of 2 mg/mL and 
filter sterilized by passing through a 2 µm seringe filter. Final concentration was 
determined by measuring the absorvance with a NanoDrop 1000 spectrophotometer, 
using the extinction coefficient of wt-TTR, ε280 = 7.76 x 104 M-1. A limulus amebocyte 
lysate-based assay (E-Toxate Test, Sigma, MO, USA) was used to confirm that the 
protein was endotoxin-free. 
 
 
 
3. Preparation and characterization of TTR amyloidogenic aggregates 
 
In the literature, several methods have been described for the production of oligomeric 
aggregates. Fibrillogenesis depends on various conditions such as temperature, protein 
concentration, ionic strength, agitation and pH [265]. The misfolding of the protein is an 
essential step. In the case of TTR, the most common method is based on the acidification 
of the protein solution to mildly acidic pH (~4-5) to mimic the lysosomal milieu, as it may 
be sufficient to initiate the assembly of TTR amyloid fibrils [266]. Complete unfolding of the 
protein into monomers with HCl pH 2.0 followed by refoldig with NaCl has also been 
described [267]. Another method of achieving oligomerization is by aging the protein, with 
or without stirring, at physiological pH [268].  
In this work, three different conditions were tested to induce aggregation: moderate pH, 
unfolding and refolding (HCl and NaCl) and aging. Regardless the method used, we found 
that the fibrillation process is very complex and not always reproducible, whatever the 
method used. 
 
3.1. TTR aggregation at mild pH (4.0-5.5) 
Aggregation was induced by lowering pH to 4.0 [269], using a sodium acetate solution, or 
to pH 5.5 using trifluoroethanol and sodium acetate, methods adapted from Reixach et al. 
[229] and Bucciantini et al. [238], respectively. Different aggregation times were tested. 
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Briefly, 1,5 mg/mL TTRV30M was incubated with either 100 mM sodium acetate buffer, 
pH 4.0, as with a mixture of 10% trifluoroethanol and 50 mM sodium acetate pH 5.5, at 
room temperature and at 37ºC. At different time points, the amyloid formation process was 
followed by spectrofluorimetry with Thioflavin T (ThT).  
 
3.2. TTR aggregation by unfolding with HCl and refolding with NaCl 
A 30 µM TTRV30M protein solution was dialysed for 96 h against 10 mM HCl (pH 2.0) to 
unfold the tetramer into monomers and the aggregation was induced with NaCl, as 
described by Lindgren et al. [267]. Final concentrations of 100 mM and 50 mM of NaCl, 
well as different incubation times, were tested. At different time points, the formation of 
amyloid was evaluated by spectrofluorimetry with ThT and cross-linking assays. 
 
3.3. TTR aggregation at physiological pH followed by magnetic stirring 
A solution of 36 µM TTR V30M (2 mg/mL) in PBS pH 7.4 (Invitrogen) was filtered through 
0,2 µm Anotop syringe filters (Whatman, Kent, UK) and incubated at 37ºC for 72 hours, 
followed by vigorous stirring for 5 minutes, using a magnetic stirring bar. The size of the 
molecular species in solution was evaluated by Dynamic Light Scattering (DLS). 
Oligomers from wild-type TTR (wt-TTR) were prepared by incubating a commercial 
protein (Sigma-Aldrich) in PBS, pH 7.4 for 96 hours at 37ºC, followed by vigorous stirring 
for 25 minutes.   
 
 
 
4. Characterization of TTR amyloidogenic aggregates 
 
The formation of TTR oligomeric aggregates was evaluated by the following methods: 
 
4.1. Thioflavin T assays 
ThT assay was adapted from the method described by Nilsson [230]. Briefly, a 12,5 mM 
ThT was prepared in 50 mM Tris pH 7.8 and filter sterilized. Aliquots from the TTR 
aggregation reaction at different time points were mixed at a final concentration of 0,02 
mg/mL with the assay buffer at 25 µM ThT. The fluorescence intensity for each sample 
was measured by excitation at 440 nm and emission 482 nm, using a Spectramax Gemini 
XS Reader. An aliquot of untreated protein solution and of Tris buffer were also added to 
the ThT assay buffer and intensity measured, to serve as control sample and negative 
control, respectively. A measured intensity above the control sample is indicative of the 
presence of amyloid fibrils. 
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4.2. Chemical cross-linking assays 
Chemical cross-linking, followed by SDS-PAGE and silver staining, was performed to 
visualize the formation of TTR oligomers of different size according to the aggregation 
time [229]. Briefly, aliquots from the TTR aggregation reaction at different time points were 
mixed at a final concentration of 0,4 mg/mL with a 2.5% solution of glutaraldehyde, and 
incubated for 5 min at 37ºC. The reaction was terminated by addition of 1 M Tris-HCl, pH 
8.0 to a final concentration of 100 mM. The samples were evaluated by SDS-PAGE and 
silver staining. 
 
4.3. Dynamic light scattering (DLS) 
DLS measurements were performed at 25ºC in a Malvern Zetasizer Nano ZS (Malvern, 
Worcestershire, UK) [268] to characterize tetrameric (time zero) and oligomeric TTR 
V30M preparations. Each sample was measured three times; average distributions are 
presented. 
 
 
 
5. Cell toxicity, apoptosis and caspases 3/7 assays 
 
It has been postulated that oligomeric species, rather than mature fibrils, induce 
citotoxicity in vitro. Mainly neuronal cells (neuroblastoma) [106, 229, 250, 270-272], and 
primary human umbilical vein endothelial cells (HUVECs) [246] have been used in these 
cytotoxicity studies. In this work we used both immortalized and primary cell lines to 
evaluate the cytotoxic effect of the oligomeric TTR aggregates in these cells in terms of 
cell viability, apoptosis and activity of caspases 3/7. Three distinct aggregation methods 
were tested in order to establish the best conditions.   
 
5.1. MTT and MTS cell viability assays 
Cells were plated into 96-well plates in complete cell medium (EGM-MV supplemented 
with 10% FBS for RPC or RPMI 1640 supplemented with GlutaMax and 10% FBS for all 
the other cell types) at a density of 3 x 103 cells per well and incubated overnight at 37ºC 
and 5% CO2. The next day the medium was removed and 100 μL of fresh medium with 
0.5% FBS and 2 μM of each protein preparation added. The non-radioactive cell 
proliferation assays MTT (Promega, Wisconsin, USA) or MTS (Promega, Wisconsin, 
USA) were performed after 24, 48 and 72h of incubation, according to the manufacturer's 
instructions. The absorvance was read in a microplate reader at 580 nm for the MTT 
assay and 490 nm for the MTS. The result was expressed as “percentage of living cells” 
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relative to that seen in control using the expression 100 × (ODsample - 
ODblank)/(ODcontrol - ODblank). The ODblank was established from the average of the 
wells containing only medium. Average values and SD were calculated from triplicate 
determinations. 
 
5.2. Annexin V apoptosis assays 
Renal progenitor cells (RPC) were plated at a density of 100.000 cells/well in a 6-well 
plate in EGM-MV with 20% FBS and incubated overnight at 37ºC and 5% CO2. The cell 
medium was changed to EBM without serum and the cells incubated for 7 h. Protein 
preparations (2 μM) diluted in EBM with 0.5% FBS were added to each well and the cells 
incubated for 48 and 72 h. The cells were detached, washed with PBS and resuspended 
in FACS Buffer (10 mM HEPES, 140 mM NaCl, 2 mM CaCl2, pH 7.4) at 1 x 10
6 cells/mL. 
Cells were stained with Annexin V-APC (eBioscience BMS306APC/100) and propidium 
iodide (PI) (Invitrogen) at a final concentration of 5 µg/mL and incubated for 15 min at 
room temperature, then kept on ice. Cell were analysed by flow cytometry in a BD LSRII 
flow cytometer (BD Biosciences). 
 
5.3. Caspases 3/7 assays 
SH-SY5Y, Hep3B and RPE cells were plated as for the MTS assay. 2 μM of each protein 
preparation, diluted in RPMI 1640 with 0,5% FBS was added to the respective wells. After 
24 h of incubation at 37°C, the Caspase-Glo 3/7 Assay (Promega, Wisconsin, USA) was 
performed to determine the activity of caspases 3/7, according to the manufacturer's 
instructions. Luminescence was read in a Vitor3 spectrophotometer (Perkin Elmer) and 
the activity of caspases 3/7 was expressed in luminescence units. Average values and SD 
were calculated from triplicate determinations.  
 
 
 
6. Influence of TTR oligomeric aggregates in the cell cycle and differentiation 
capacity of renal progenitor cells 
 
6.1. Cell Cycle analysis 
RPC were plated at 1 x 105 cells/well in a 6-well plate the day before the experiment. 
Solutions of 2 μM TTRV30M diluted in EBM with 0,5% FBS were added to each well. The 
cells incubated for 48 and 72 h with the stimuli, then were detached, washed and 
resuspended in 100 µL 50% FBS in PBS, then fixed at 4ºC for 1 hour with 300 µL cold 
70% ethanol added dropwise, washed, stained with Propidium Iodide (50 µg/mL) in 
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presence of RNAse 100 µg/mL and analyzed by flow cytometry in a BD LSRII flow 
cytometer (BD Biosciences). 
 
6.2. Differentiation of RPC into podocytes  
Following Ronconi et al. [256], RPC were plated at 8 x 104 cells/well in a 6-well plate with 
the differentiation medium VRAD: DMEM-F12 supplemented with 0,5% FBS, 100 nM 
vitamin D3, and 100 μM ATRA. For the non differentiation control, the medium used was 
EBM with 0,5% FBS. The oligomeric protein was diluted in the correspondent media, at a 
final concentration of 2 µM. Differentiation was induced for 24 and 48 h. The cells were 
detached, counted and centrifuged. The pelleted cells were used for RNA extraction, RT-
PCR and real time PCR. Differentiation was evaluated by quantification of nephrin and 
glyceraldehyde-3-phosphate dehydrogenase gene expression in taqman real-time PCR 
assays, using standard curves generated with serial dilutions of the same positive sample. 
 
 
 
7. Influence of TTR oligomeric aggregates on the expression of the 
erythropoietin gene in Hep3B and RPE cells 
 
The human hepatoma Hep3B cell line expresses erythropoietin (EPO) both in a 
constitutive and an inducible oxygen-dependent manner [273]. Due to the lack of an 
adequate renal EPO-producing cell line, we used a human hepatoma Hep3B culture 
model to evaluate the influence of TTR oligomeric aggregates directly on the expression 
of the erythropoietin gene, both in normoxia and in simulated hypoxia, using the 
panhydroxylase inhibitor dimethyloxalylglycine (DMOG). Retinal pigment epithelial (RPE) 
cells are known to be local EPO producers, so primary cell cultures of RPE were also 
used. 
 
Hep3B and RPE cells were plated into 12-well plates in RPMI supplemented with 10% 
FBS at a density of 8 x 104 cells per well. The next day the medium was removed and 
each TTR preparation, diluted in RPMI 1640 supplemented with 0,5% FBS, was added in 
quadruplicate at a final concentration of 2 μM. After 16 h of incubation at 37ºC, the 
panhydroxylase inhibitor dimethyloxalylglycine (DMOG) (Sigma) was added to 2 wells of 
each preparation to a final concentration of 200 μM, to mimic hypoxia, and cells incubated 
for another 8 h. 
Total RNA was extracted using Trizol Reagent (Invitrogen), according to manufacturer’s 
instructions. RNA was quantified by measuring the absorbance at 260 nm, and was 
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treated with 0,2 units of RNase-free DNase I (Promega) per µg of RNA, was further 
purified by ethanol precipitation and resuspended in RNase-free water. First-strand cDNA 
was synthesized from 1 μg of RNA using Superscript III DNA polymerase (Invitrogen). 
Real-time PCR quantification was performed in a Corbett Rotor-Gene 6000 (Qiagen, 
Hilden, Germany) using Taqman Gene Expression Master Mix (Life Technologies, CA, 
USA). A fragment of the EPO gene was amplified using Lux Primers (Invitrogen) [274] 
with the following sequences: forward primer 596F (5’-CTGGGAGCCCAGAAGGAAG-3’) 
and reverse primer 648RL (5'-CACTCCAGCAGTGATTGTTCGGAGTG-3', internally 
labeled with FAM). The cycling conditions were: one cycle at 50ºC for 18 min; one cycle at 
95ºC for 10 min; 45 cycles of 95ºC for 20 s, 58ºC for 40 s, 72ºC for 40 s. The specificity of 
the amplification was confirmed by sequencing the PCR amplicons and by melting curve 
analysis. Results were normalized to endogenous TATA-binding protein mRNA (TBP), 
using the probe/primer set Hs00427620_m1 (Life Technologies) for taqman gene 
expression assays. 
 
 
 
8. Influence of TTR oligomeric aggregates on the activity of the EPO promoter  
 
8.1. Cloning of the erythropoietin promoter  
A DNA fragment of 1848 bp, containing the base pairs -1772 to 76 relative to the EPO 
transcription site which includes the recognition sites for the transcription factors GATA-2 
and NF-kB, was PCR amplified from genomic DNA of a normal individual, that gave 
informed consent for research use, using the following primers: forward, 5’-
GCCAGATCCCGCAATACTCAC-3’; reverse, 5’-CTGGAGGAGAGGGCGGCTGTC-3’. 
The PCR product (figure 8A) was purified using a commercial kit (Promega) and 
sequenced using the “BigDye Terminator v3.1 Cycle Sequencing Kit” (Applied 
Biosystems). The fragment of the EPO promoter was first subcloned into the pDrive 
Cloning Vector (Qiagen) (shown on figure 8B), and then transferred into the MluI-XhoI 
restriction site of the pGL3-basic vector (Promega). The insert was verified by restriction 
enzyme digestion with MluI and XhoI, and bidirectional Sanger sequencing. A scheme of 
the constructed vector Epo-Prom-pGL3 is depicted on figure 9. 
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Figure 8 – Electrophoresis in 1,5% agarose gel, stained with ethidium bromide 1 µg/mL of 
the pcr product of the EPO Promoter, comprising base pairs -1772 to 76 relative to the 
EPO transcription site (A); insert of the EPO Promoter pcr product cloned into the pDrive 
Cloning Vector and verify by cutting the plasmid with the restriction enzyme EcoRI (B). 
 
 
 
 
Figure 9 – Scheme of the reporter vector Epo-Prom-pGL3 constructed for the luciferase 
assays. The vector contains a fragment of the EPO promoter spanning the sequence 
binding sites for GATA-2 and NF-kB, which are known to negatively regulate EPO gene 
expression in normoxia.  
 
 
 
Materials and Methods 
 
55 
 
8.2. Transfection with Epo-Prom-pGL3 
Hep3B cells were plated into 24-well plates in complete cell medium at a density of 9 x 104 
cells per well on the day before the experiment. To evaluate the influence of TTR V30M 
on the activity of EPO promoter, Hep3B cells were cotransfected with 7 ng of the control 
Renilla luciferase plasmid pTK-RL (Promega) and 350 ng of the Epo-Prom-pGL3 plasmid. 
Transfections were done with Lipofectamine 2000 (Invitrogen), using a ratio of 1:3 of DNA 
(µg) to lipofectamine (µL) respectively. After 18 hours, the medium was removed and 
each TTR preparation was added, at a final concentration of 2 μM. Cells were incubated 
for 24 h and luciferase activities were measured with the Dual-Luciferase Assay Kit 
(Promega), using a Victor 3 multilabel reader (PerkinElmer). Fold induction was calculated 
using Renilla luciferase control normalized values. 
 
8.3. Co-transfection with Epo-Prom-pGL3 and pCG-ATF3 
Hep3B cells were plated into 24-well plates in complete cell medium at a density of 9 x 104 
cells per well on the day before the experiment. To evaluate the possible influence of the 
activating transcription factor ATF3 on the activity of EPO promoter in Hep3B cells 
exposed to TTRV30M, cells were cotransfected with 14 ng of the control Renilla luciferase 
plasmid pTK-RL (Promega), 350 ng of the Epo-Prom-pGL3 plasmid and 350 ng of pCG-
ATF3 (kindly offered by professor Tsonwin Hai from the Ohio State University). 
Transfections, incubations with 2 μM of TTR preparations and measurements of luciferase 
activities were done as described in the previous section. Fold induction was calculated 
using Renilla luciferase control normalized values. 
 
8.4. Immunofluorescence for NF-kB and GATA-2 on Hep3B cells 
Hep3B cells were plated on 4-well chamber slides (Lab-Tek) at a density of 7,5x103 
cells/well and incubated overnight in complete cell media. Solutions of oligomeric or 
tetrameric TTRV30M, 2 μM in RPMI with 0,5% FBS, were added to each well and the 
cells incubated for 24 hours. The cells were fixed with 4% paraformaldehyde for 10 
minutes and permeabilized with cold methanol at -20ºC for 10 min. Cells were washed 
with PBS between each incubation. Blocking was performed with 5% BSA in PBS for 1 
hour followed by incubation with the primary antibody diluted in 1% BSA for 3 hours at 
room temperature. The antibodies used were rabbit anti-human NF-kB p65 polyclonal 
antibody (ab7970, Abcam) diluted 1:400 and rabbit anti-human GATA-2 polyclonal 
antibody (H-116, Santa Cruz Biotechnology) diluted 1:600. Cells were washed with PBS 
and incubated for 1 hour with the secondary antibody (A11008, Alexa Fluor 488 goat anti-
rabbit IgG, Life Technologies) diluted 1:600 in 1% BSA. Slides were mounted in 
Fluoroshield with DAPI (Sigma) and analyzed using a fluorescence microscope (Leica). 
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8.5. Immunohistochemistry for NF-kB and GATA-2 on FAP renal biopsies 
Immunohistochemistry (IHC) was performed on 4 μm thick formalin-fixed paraffin-
embedded sections using standard methods. Treatment with 0.01 M Sodium Citrate 
Buffer (pH 6.0) was performed to enhance antigen retrieval. Blocking was performed with 
5% BSA in PBS for 1 hour at room temperature, followed by incubation with the antibodies 
diluted in 1% BSA in PBS for 3 hours at room temperature. The antibodies used were 
rabbit anti-human NF-kB p65 polyclonal antibody (anti-NF-kB, Abcam) diluted 1:400, and 
rabbit anti-human GATA-2 polyclonal antibody (Santa Cruz) diluted 1:600. Detection was 
carried out with Dako REAL EnVision Detection System, Peroxidase/DAB+, Rabbit/Mouse 
(Dako). 
 
 
 
9. Statistical analysis 
Results of replicated experiments were expressed as mean±SD. Means were compared 
using the Student’s t-test. P values <0.05 were considered statistically significant. 
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1. Production and evaluation of TTRV30M aggregates   
 
Recombinant TTRV30M protein was obtained using an E. coli expression system. The 
synthetic vector pJexpress401:34985–TTRV30M_v2_opt (pJT, DNA2.0 Inc.) codes for a 
fusion protein containing the human TTR with the Met30 mutation and a poly-histidine tag 
that enables its purification by IMAC, and that can be subsequently removed.  
 
The recombinant protein accumulates inside the cell, in inclusion bodies, a process that 
was minimized by decreasing the incubation temperature to 30ºC at the time of protein 
expression induction with IPTG. After lysing the cells, the protein was released to the 
medium in soluble form and the supernatant was directly applied to the Ni2+ sepharose 
column. A linear gradient of imidazole was run through the column, and the TTRV30M 
protein was eluted with a concentration of imidazole of approximately 300 mM, in an 
almost pure form (figure 10). On average we obtained 40 mg of TTRV30M-HIS tagged / L 
of cell culture, which was equivalent to approximately 2 mg of TTRV30M-HIS tagged per 
gram of bacterial pellet. 
 
 
 
Figure 10 – IMAC elution profile of the rh-TTRV30M; lane 1: MW ladder; lanes 2-5: 
flowthrough; lanes 6-15: linear gradient of imidazole; lanes 10-14: fractions containing 
TTRV30M. 
 
 
After TEV protease treatment, the histidine tags and protease were removed in the end by 
passing the reaction mixture through a second Ni2+ sepharose column, to obtain a 
relatively pure cleaved TTRV30M (figure 11).  
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Figure 11 – Proteolysis of his-tagged TTRV30M by TEV protease (A) and cleaved 
TTRV30M after IMAC purification and concentration by ultrafiltration (B); lanes 1 and 9: 
MW ladder; lane 2: TEV793; lanes 3 and 6: his-tagged TTRV30M; lanes 4 and 5: 
completed proteolysis reaction, before IMAC purification; lane 7: peptides and TEV that 
remained attached to the column, eluted with 400 mM imidazole; lanes 8 and 10: purified 
TTRV30M; lane 11: TTRV30M purified and concentrated by ultrafiltration. 
 
 
To further increase the purity of the protein, two more chromatographic steps were 
performed: an ion exchange chromatography, using Q-Sepharose FF, followed by a 
polishing gel filtration chromatography, to eliminate possible protein aggregates that may 
be formed during the purification process. The last step was the chromatographic removal 
of LPS. A limulus amebocyte lysate-based assay (E-Toxate Test, Sigma, MO, USA) was 
used to confirm that the final protein batch was endotoxin-free.  
 
Due to the extensive purification process, involving two IMAC chromatographies, one ion 
exchange chromatography, a gel filtration chromatography and finally detoxification, the 
yield of purified TTRV30M was approximately 45% of the initial TTRV30M-HIS tagged 
pool. We obtained an average of 18 mg TTRV30M / L of cell culture. Although the yield is 
relatively low, we obtained a highly pure protein to be used on the cell culture assays.  
A                       B 
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2. Evaluation of TTRV30M amyloidogenic aggregates  
 
Throughout the work, three different methods were used to produce the TTRV30M 
aggregates, according to the literature: acidification of the protein solution to mildly acidic 
pH (~ 4-5) [266], complete unfolding of the protein into monomers with HCl pH 2.0 
followed by refoldig with NaCl [267], and aging the protein at 37ºC in physiological pH, 
followed by 5 minutes magnetic stirring, a method that we adapted from the procedure 
described by Ferreira et al. [268]. The reason for testing different methods was the poor 
reproducibilitty of the oligomerization process. Regardless the method used, we found that 
the fibrillation process to be very complex and difficult to reproduce. 
 
Fibrillation of TTR seems to proceed by disruption of the tetramer into monomers, which 
undergo a conformational change, and are the building blocks for the formation of fibrils 
[224, 275-278]. Other models implicate the dimer [279] or the oligomers [280] as the 
building blocks. Irrespective of the model proposed, there are common evidences 
regarding which species are responsible for the cytotoxicity induced in the tissues. The 
intermediate species or small soluble oligomeric aggregates that are formed during the 
fibrillation process are toxic to cells in a free radical dependent manner [271], while the 
amyloid fibrils themselves are not toxic to the cells. Amyloid fibrils have been proposed to 
be protective, by storing the misfolded proteins in non-toxic fibrils and thereby removing 
toxic protofilaments from circulation [271]. 
 
To evaluate the formation of amyloidogenic TTRV30M aggregates, Thioflavin T (ThT), 
chemical crosslinking or dynamic light scattering (DLS) were used.  
 
Upon addition of thioflavine T to suspensions of TTRV30M incubated with either 100 mM 
Acetate Buffer, pH 4.0, with a mixture of 10% trifluoroethanol (TFE) and 50 mM sodium 
acetate pH 5.5, or with HCl pH 2.0 and 100 mM NaCl, the fluorescence intensity increases 
(figure 12), indicating formation of amyloidogenic species. 
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In the case of acetate buffer at pH 4, the intensity of fluorescence increased slowly over 
time (figure 12A). On the other hand, for the TTRV30M incubated with either a mixture of 
TFE and sodium acetate pH 5.5 (figure 12B) or with HCl and NaCl (figure 12C), the 
aggregation reaction started immediately. Figure 13 shows dissociation of the TTRV30M 
tetramer into monomers as a function of pH and the rapid formation of larger species upon 
addiction of NaCl. These methods, based on acidification of the protein solution to induce 
amyloid formation are described in the literature and used to produce cytotoxic 
aggregates. 
 
We tested these aggregated TTRV30M preparations on cell culture assays. Despite 
positive ThT results, we had no significant cytotoxic effect with the solutions prepared with 
acetate buffer pH 4.0 or with acetate buffer pH 5.5 and TFE. On the other hand, we 
obtained a moderate cytotoxic effect with the protein solution prepared by acidification 
 
Figure 12 – Time course of TTRV30M aggregation 
followed by ThT fluorescence, induced by acetate 
buffer pH 4.0 (A), acetate buffer pH 5.5 and 10% TFE 
(B) or HCl pH 2.0 followed by 100 mM NaCl (C). 
Figure 13 – Cross-linking 
with glutaraldehyde followed 
by SDS-PAGE with silver 
staining showing TTRV30M 
tetramer dissociation with 
HCl at pH 6 (2), 5 (3), 4 (4), 
3 (5), 2 (6) and formation of 
aggregates at pH 2 and 
incubation for 5 minutes with 
100 mM NaCl (7).  
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with HCl and induction of aggregation with NaCl for 5 minutes. Interestingly, the solutions 
prepared with the acetate buffers and TFE usually precipitated immediately, indicating 
formation of large amorphous aggregates. On the other hand, the solution of TTRV30M in 
HCl was completely transparent, even after the addiction of NaCl, probably due to the 
formation of soluble oligomers. Although the ThT assays done did indicate the presence 
of amyloid-like species, no correlation with the cytotoxicity induced by the protein solutions 
was apparent. 
 
As the aim of our work was to use the TTRV30M oligomeric preparations on cell culture 
assays, and to more accurately approximate the physiological environment, we also 
tested the method based on aging the protein solution while maintaining the physiological 
pH, as described by Ferreira et al [268]. We made a slight change, by aging the 
TTRV30M solution at 37ºC under stagnant conditions and then stirring vigorously for only 
5 minutes.  
 
DLS was used to evaluate the size of the TTRV30M species in solution. Soluble 
tetrameric TTRV30M, diluted in PBS at pH 7.4, at time 0 showed a single peak at 
approximately 7 nm (figure 14A). To induce the formation of oligomers, TTRV30M was 
incubated for 72 hours at 37ºC, followed by 5 minutes of vigorous stirring. At the end of 
the 72 h incubation, the presence of oligomeric aggregates with 150 nm was noted (figure 
14B), that progressed very rapidly to larger 300 nm aggregates after vigorous stirring, 
representing then the majority of the TTR preparation (figure 14C). A preparation stirred 
for 7 days showed a predominance of species of approximately 600 nm (figure 14D). 
However, this solution did not induce cytotoxicity, unlike the solutions containing species 
of 150 and 300 nm. 
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Figure 14 - DLS analysis of TTR V30M aggregation for 0 (A), 3 days at 37º C under 
stagnant conditions (B), 3 days at 37º C under stagnant conditions followed by 5 minutes 
of magnetic stirring (C), 7 days of magnetic stirring (D). Preparation represented in (C) 
has a high percentage of small oligomeric species (78%) so was the one used for the cell 
culture assays. 
 
 
TTRV30M is a tetrameric protein with an extensive β-sheet conformation, prone to 
dissociation into intermediate molecular species during amyloid fibrillogenesis. Pires et al. 
reported that distinct annular oligomeric intermediates formed along both the assembly 
and disassembly pathways of TTR, that undergo morphological transitions into spheroid 
oligomers and protofibrils [228]. We induced protein fibrillation in vitro by aging a solution 
of TTRV30M at physiological pH and temperature, which is evidence for the natural 
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instability of the quaternary structure of the protein and its tendency to aggregate and form 
amyloidogenic fibers. We saw that after 72 hours of incubation under stagnant conditions, 
species of molecular size corresponding to early oligomers are already in solution, albeit 
in small amounts relative to the predominant tetrameric form. Stirring this solution for 5 
minutes was sufficient to trigger the rapid formation of larger species. 
 
TTRV30M preparations obtained by aging at physiological pH followed by magnetic 
stirring for 5 minutes (figure 14C) and preparations obtained by dissociation of the 
tetramer into monomers at pH 2.0 followed by refolding with NaCl (figure 12C) were the 
final preparations of oligomeric TTRV30M used for the cell culture assays, as we saw that 
these were the most cytotoxic species. 
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3. TTRV30M oligomeric aggregates compromise cell viability of both 
immortalized SH-SY5Y, Hep3B and HEK293T cell lines, as well as of primary 
RPE and RPC cells 
 
The immortalized cell lines Hep3B, SH-SY5Y and HEK293T, the primary RPE cells and 
the renal progenitor cells RPC were exposed to TTR preparations in order to evaluate cell 
viability. Oligomeric preparations were prepared by unfolding with HCl and refolding with 
NaCl, or by aging the protein solution at pH 7.4 and 37ºC followed by 5 minutes of stirring. 
Hep3B and SH-SY5Y were exposed to oligomers produced by both methods. HEK293T 
and RPC were exposed only to oligomers produced by unfolding and refolding. RPE cells 
were exposed only to oligomers produced by aging the TTRV30M at physiological pH and 
temperature.  
 
 
3.1. Cell viability assays 
 
A non-radioactive cell proliferation assay (MTT or MTS) was used to evaluate the 
cytotoxicity of TTRV30M preparations. The results obtained for each cell type were similar 
regardless of the method used, so we calculated the average of all the experiments and 
respective replicates in which these oligomers were cytotoxic, for each cell type. 
Preliminary experiments were performed with RPC cells exposed to protein 
concentrations of 0.5, 1.5 and 3 µM and with an incubation time of 72 hours. A 
concentration dependent reduction in cell viability was observed (figure 15).  
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Figure 15 - Non-radioactive Cell Proliferation Assay in the human RPC exposed for 72 
hours to concentrations of 0.5, 1.5 and 3 µM of oligomeric TTRV30M. The results are 
represented as percentage of living cells for each condition relatively to control (cell 
medium). Values are means of triplicates. Error bar= SD. 
 
 
In order to reach a compromise between the effect of the protein preparations on the cells 
and the quantity of protein spent on each experiment, a concentration of 2 µM was chosen 
for all the subsequent experiments throughout the work.  
 
A modest but statistically significant reduction in cell viability was observed after 24, 48 
and 72 hours in the presence of oligomeric TTRV30M when compared to the control (cell 
media alone), in the five cell types evaluated (figures 16-18 and tables 3-5). Detailed 
information about the percentages of living cells relatively to controls, and respective 
standard deviations and student’s t-test values are presented in tables 3-5. Comparing 
cell viability between the oligomeric and tetrameric TTR preparations, the 24 hours 
incubation time gave more consistent results, showing a statistically significant reduction 
of cell viability for all cell types in the presence of the oligomeric TTRV30M preparations. 
Despite being a modest reduction (varying from 7% for RPC to 13% for Hep3B and RPE), 
oligomeric TTR aggregates reduced cell viability consistently and to a similar amount 
independently of the cell type, after 24 hours of incubation. Less consistent results were 
obtained for longer incubation times. 
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Figure 16 - Non-radioactive Cell Proliferation Assay in the human cell lines SH-SY5Y (A) 
and HEK293T (B) exposed for 24, 48 or 72 hours to tetrameric and oligomeric TTR V30M 
preparations. The results are represented as percentage of living cells for each condition 
relatively to control (cell medium). p value was calculated using student’s t-test. *p<0,05 
with respect to tetrameric TTR V30M. Values are means of replicates from independent 
experiments. Error bar= SD. 
 
 
 
Figure 17 - Non-radioactive Cell Proliferation Assay in the human cell line Hep3B exposed 
for 24, 48 or 72 hours to tetrameric and oligomeric TTR V30M preparations (A) and for 24 
hours to tetrameric and oligomeric wild-type TTR. The results are represented as 
percentage of living cells for each condition relatively to control (cell medium). p value was 
calculated using the student’s t-test. *p<0,05 with respect to tetrameric TTR V30M. Values 
are means of replicates from independent experiments. Error bar= SD. 
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Figure 18 - Non-radioactive Cell Proliferation Assay in human renal progenitor cells (A) 
and in human retinal pigment epithelial cells (B) exposed to tetrameric and oligomeric TTR 
V30M preparations, as described on Materials and Methods. The results are represented 
as percentage of living cells for each condition relatively to control (cell medium). p value 
was calculated using the student’s t-test. *p<0,05 with respect to tetrameric TTR V30M. 
Values are means of replicates from independent experiments. Error bar= SD. 
 
 
For 48 and 72 hours the results were not always very reproducible, particularly regarding 
the tetrameric preparations, which induced toxicity after 48 and 72 hours in HEK293T and 
RPC cells. In fact, tetrameric TTR may quite possibly be dissociating into monomers 
during cell culture incubation times longer than 24 hours [278], inducing cell toxicity. The 
fact that the cytotoxicity induced at longer incubation times occurred particularly on 
HEK293T and RPC cells may also be related to the varying capacity of different cell types 
to recover from cellular damage at longer exposure times, as described by Cecchi et al. 
using HypF-N toxic aggregates [281]. 
A preparation of TTRV30M incubated for 72 hours at 37ºC was analysed by DLS and 
showed that TTRV30M has a tendency to destabilize and form oligomeric species, as 
shown in figure 14B (section 2 of the Results). Although the oligomers exist in a small 
percentage (16%) when compared to the tetrameric form, this preparation was also able 
to induce a reduction of cell viability on Hep3B cells, although to a smaller extent than the 
preparation that was stirred for 5 minutes (figure 19).  
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Figure 19 - Non-radioactive Cell Proliferation Assay in Hep3B cells exposed for 24 hours 
to tetrameric TTRV30M, TTRV30M incubated at 37ºC for 72 h under stagnant conditions 
and TTRV30M incubated at 37ºC for 72 h under stagnant conditions followed by 5 
minutes of stirring. The results are represented as percentage of living cells for each 
condition relatively to control (cell medium). p value was calculated using student’s t-test. 
*p<0,05 with respect to control. Values are means of triplicates. Error bar= SD. 
 
 
Oligomers produced from wild-type TTR (wt-TTR) were also evaluated, on Hep3B cells. 
They induced a reduction of 7.1±3.1% in the Hep3B viability relatively to tetrameric wt-
TTR (figure 17B), suggesting that cytotoxicity is induced by oligomeric species regardless 
of the precursor protein used.  
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Table 3 – Results of cell viability assays perfomed on human cell lines SH-SY5Y and 
HEK293T. Cells incubated for 24, 48 or 72 hours in presence of 2 µM tetrameric or 
oligomeric TTRV30M. Values are means and standard deviations of replicates from 
independent experiments. p values were calculated using student’s t-test. 
 
 SH-SY5Y 
 Oligomeric TTRV30M Tetrameric TTRV30M 
Incubation time 24 h 48 h 72 h 24 h 48 h 72 h 
% Living cells relatively to control 90±5% 89±7% 86±5% 101±10% 98±9% 100±13% 
p (T-test) relatively to control 7,2x10
-7
 5,7x10
-6
 1,5x10
-8
 0,70 0,40 0,87 
p (T-test) relatively to tetrameric TTRV30M 1,6x10
-4
 1,3x10
-3
 2,1x10
-4
 - - - 
Number of replicates 17 20 14 19 23 20 
 HEK293T 
 Oligomeric TTRV30M Tetrameric TTRV30M 
Incubation time 24 h 48 h 72 h 24 h 48 h 72 h 
% Living cells relatively to control 90±6% 86±13% 76±11% 102±5% 95±12% 79±19% 
p (T-test) relatively to control 2,3x10
-2
 3,9x10
-3
 2,9x10
-4
 0,52 0,16 1,1x10
-2
 
p (T-test) relatively to tetrameric TTRV30M 6,5x10
-3
 0,10 0,66 - - - 
Number of replicates 5 11 9 7 12 10 
 
 
 
Table 4 – Results of cell viability assays perfomed on the human cell line Hep3B. Cells 
incubated for 24, 48 or 72 hours in presence of 2 µM tetrameric or oligomeric TTRV30M, 
and for 24 hours in presence of 2 µM tetrameric or oligomeric wild-type TTRV30M (wt-
TTR). Values are means and standard deviations of replicates from independent 
experiments. p values were calculated using student’s t-test. 
 
 Hep3B 
 
Oligomeric                   
TTRV30M 
Tetrameric                   
TTRV30M 
Oligomeric 
wt-TTR 
Tetrameric 
wt-TTR 
 
24 h 
 
90±2% 
 
8,6E-4 
 
2,0E-2 
4 
Incubation time 24 h 48 h 72 h 24 h 48 h 72 h 24 h 24 h 
% Living cells 
relatively to control 
87±6% 93±4% 89±2% 100±6% 94±13% 98±8% 93±3% 100±4% 
p (T-test) relatively 
to control 
6,8x10
-10
 1,3x10
-4
 9,5x10
-4
 0,87 8,9x10
-2
 0,42 3,6x10
-3
 0,50 
p (T-test) relatively 
to tetrameric TTR 
1,1x10
-8
 0,8 5,0x10
-3
 - - - 1,4x10
-3
 - 
Nº of replicates 21 18 7 23 18 11 8 8 
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Table 5 – Results of cell viability assays perfomed with human renal progenitor cells 
(RPC) and retinal pigment epithelial cells (RPE). RPC incubated for 24, 48 or 72 hours 
and RPE incubated for 24 hours in presence of 2 µM tetrameric or oligomeric TTRV30M. 
Values are means and standard deviations of replicates from independent experiments.  
 
 RPC  RPE 
 
Oligomeric                 
TTRV30M 
Tetrameric                   
TTRV30M 
 
Oligomeric 
TTRV30M 
Tetrameric 
TTRV30M 
 
24 h 
 
90±2% 
 
8,6E-4 
 
2,0E-2 
4 
Incubation time 24 h 48 h 72 h 24 h 48 h 72 h  24 h 24 h 
% Living cells 
relatively to control 
91±4% 89±10% 88±9% 98±8% 93±8% 89±16%  90±2% 104±7% 
p (T-test) relatively 
to control 
8,4x10
-4
 1,8x10
-5
 6,9x10
-4
 0,46 0,02 0,07  8,6x10
-4
 0,27 
p (T-test) relatively 
to tetrameric 
TTRV30M 
4,5x10
-2
 0,15 0,77 - - -  2,0x10
-2
 - 
Nº of replicates 9 27 16 8 14 11  4 4 
 
 
 
From these experiments it can be seen that oligomeric TTR aggregates reduced cell 
viability independently of the cell type after 24 hours of incubation. 
Although the results presented here were very consistent, we believe it is important to 
state that not all the preparations used for the cell culture assays produced cytotoxic 
aggregates. Some preparations had no effect on the cells, despite being prepared exactly 
the same way as those that were cytotoxic. We cannot fully explain this observation, but 
we believe this is due to the particular instability of the protein structure and the stockastic 
nature of the oligomerization process, that does not always result in the formation of toxic 
species. These experiments were ignored and the results presented here are the means 
of replicates from independent experiments in which the oligomeric preparations induced 
cytotoxicity. 
 
 
 
3.2. Caspase 3/7 assays  
 
In order to understand if the mechanisms underlying cell toxicity were related to apoptosis, 
caspases 3/7 assays were performed. 
It has been reported that oligomeric aggregates induce apoptosis through activation of 
caspase 3. So, to understand how cell viability was being compromised in our cell models, 
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a Caspase-Glo 3/7 assay was used to evaluate the induction of apoptosis by TTRV30M in 
Hep3B, SH-SY5Y and RPE cells.  
 
 
 
 
 
Caspase activity was significantly increased in the three cell types exposed to 2 µM 
oligomeric TTRV30M for 24 hours when compared to cell culture media (figure 20). The 
most pronounced increase in caspase activity was seen for the Hep3B cells (92.3±6.0%, 
p=7.7x10-5, relatively to cell culture media and 35.4±4.2%, p=2.4x10-5, relatively to 
tetrameric TTRV30M). Increased caspase activity was also observed with exposure to the 
tetrameric form in the three cell types.  
Figure 20 - Caspases 3/7 activity in 
Hep3B (A), SH-SY5Y (B) and RPE 
(C) cells exposed for 24 hours to 2 
μM tetrameric TTRV30M, 2 μM 
oligomeric TTRV30M and control. 
Luminescence units are 
proportional to the amount of 
caspase activity. p value was 
calculated relatively to control, 
using student’s t-test. Values are 
means of triplicates. Error bar= SD. 
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The caspase assay is rather more sensitive than the MTS assay, therefore it is not 
surprising that some activity is detected after 24 hours of incubation at 37ºC with 
tetrameric TTRV30M in the caspase assay, but not with MTS. As already mentioned for 
the viability assays, tetrameric protein solution may begin to form monomers or oligomers 
that even in small quantities could be sufficient to activate caspases. Our assumption is 
supported by the fact that DLS of TTRV30M after 72 hours incubation at 37ºC showed 
that this protein has a tendency form oligomeric species, and was able to induce a 
reduction of cell viability (figures 14B and 19). 
 
Early oligomeric aggregates have been shown to be more cytotoxic than mature amyloid 
fibrils [229, 270-272]. Similar reduction levels of cell viability induced by the oligomeric 
TTRV30M preparations after 24 hours of incubation were observed for the five different 
cell types evaluated: human hepatoma cell line Hep3B, human neuroblastoma cell line 
SH-SY5Y, human embrionic kidney HEK293T, human renal progenitor cells (RPC) and 
primary retinal pigment epithelial cells (RPE). For three of these cell types: Hep3B, SH-
SY5Y and RPE, a caspase assay was performed. Together with the reduction of cell 
viability, a concomitant increase in caspase 3/7 activity was seen in the cells exposed to 
oligomeric TTRV30M aggregates.  
 
These results agree with previous studies performed using other cell types, mainly 
neuronal cells (neuroblastoma) [106, 229, 250, 270-272], and primary human umbilical 
vein endothelial cells (HUVECs) [246], and implicate apoptosis in loss of viability. 
Interestingly, this cytotoxic effect induced by aggregates seems to be independent of the 
cell type, contrary to what was reported by Cecchi et al. Using aggregates of HypF-N, a 
prokaryotic peptide domain, that display the same properties of aggregates produced by 
disease-associated peptides and proteins, they showed that different cell lines have 
different susceptibilities to damage and apoptosis, and this susceptibility was inversely 
related to membrane content in cholesterol, to total anti-oxidant capacity of the cell and to 
the ability of the cell to maintain the balance of intracellular free Ca2+ [282]. However, the 
same group reported later that such differences are more pronounced in longer exposure 
times due to different recovering capacity from cellular damage [281]. In fact we saw a 
similar cytotoxic effect between the various cell types in the shortest exposure time to the 
aggregates. Increasing the incubation time, the results became less reproducible, an 
increased toxic effect being observed in some cases but a reduction of cytotoxicity in most 
of them. This may be due to continuing fibrillogenesis, leading to the formation of larger 
species which may no longer be toxic. According to Cecchi et al, the reduction of 
cytotoxicty at longer incubation times may also be due to recovery from cellular damage. 
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In vivo, it is known that TTR aggregates preferentially deposit in perypheral nerves, 
causing myelin destruction, and also in the heart, kidney and vitreous rather than in the 
liver. However, the mechanisms involved in this preference are not yet understood. In 
view of our citotoxicity results we can speculate that, at least in early disease stages, TTR 
aggregates may influence cell viability regardless of cell type. 
 
Oligomers generated from wild-type TTR were tested on Hep3B cells and also induced a 
reduction of cell viability. This result is in agreement with our expectations, as wild-type 
TTR is also amyloidogenic and responsible for senile systemic amyloidosis (SSA), 
causing mainly cardiac complications. With these results we can say that both V30M and 
wild-type TTR oligomeric preparations were cytotoxic, a property that may be common to 
all prefibrillar amyloid protein aggregates and apparently independent of the target cell 
type.  
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4. Renal progenitor cell proliferation is inhibited by TTRV30M oligomeric 
aggregates but maintain their capacity to differentiate into podocytes in vitro 
 
A subset of renal progenitor cells (RPC), expressing the surface markers CD133 and 
CD24, with self-renewal and multidifferentiation potential exist at the urinary pole of 
Bowman’s capsule in the adult human kidney [255]. In Familial Amyloidotic 
Polyneuropathy, amyloid deposition of mutant TTRV30M leads to renal complications, 
including nephrotic syndrome and end-stage kidney failure [283].  
Here we assessed whether RPC are vulnerable, in vitro, to TTRV30M oligomers in order 
to understand if their regenerative potential could be compromised.  
 
 
We showed (section 3.1.) that oligomeric TTRV30M aggregates reduce RPC viability by 
9±4% after 24 hours. This reduction was significant relatively to both the unexposed and 
tetrameric TTRV30M exposed controls.  
Apoptosis, necrosis and alterations in cell cycle progression were assessed by FACS 
analysis on cells treated for 48 and 72 hours. TTRV30M oligomers did not induce 
apoptosis, necrosis or alterations in cell cycle progression to the RPC cells in a significant 
extent, neither at 48 or 72 h (figure 21).  
 
 
 
 
Figure 21 - FACS analysis to evaluate apoptosis and necrosis (A) and alterations in cell 
cycle (B) in RPC treated with 2 µM oligomeric TTRV30M for 48 and 72 h. 
A 
 
 
 
 
 
 
 
 
 
B 
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CD133+CD24+ RPC have an inherent capacity to differentiate into podocytes when 
cultivated in VRAD medium. The influence of oligomeric TTRV30M on the regenerative 
capacity of these progenitor cells was assessed.  
Podocytes express nephrin so the relative expression level of this marker was evaluated 
by real-time pcr to confirm differentiation. The results varied between experiments, but on 
average we obtained similar results between the controls and the cells exposed to 
TTRV30M aggregates, both on differentiation and non-differentiation media (Figure 22).  
 
 
 
Figure 22 - Differentiation of renal progenitor cells into podocytes. Assessment by 
quantitative RT-PCR of fold increase mRNA levels for the podocyte marker nephrin and 
the housekeeping gene GAPDH. 
 
 
TTRV30M aggregates reduced proliferation of renal progenitor cells. However, in the 
apoptosis and cell cycle progression assays no significant alterations were observed. 
Also, in the differentiation experiments we saw no alterations in the expression level of the 
nephrin gene, a marker for podocytes, relatively to controls, so the inherent capacity of 
these progenitor cells to differentiate into podocytes was apparently not affected by the 
oligomers. These results are in agreement with a study of Petrakis et al. They saw, with a 
transgenic mouse model of TTRV30M-related amyloidosis, that TTRV30M deposition has 
deleterious effects on glomerular basement membrane thickness and podocyte foot 
process width, but without affecting nephrin and podocin gene expression [284].  
A study from Neri et al, using murine embryonic stem (ES) cells and haematopoietic 
progenitor (HP) cells exposed to oligomers of Aβ42 showed that ES, but not HP, 
displayed some impaired viability but their differentiation was not affected by these 
oligomers [285], which is in agreement with our results.  
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From this study we can say that TTRV30M oligomers inhibit RPC proliferation but do not 
influence their capacity to differentiate into functionally mature podocytes, and thus should 
not compromise tissue regeneration. These resident progenitor cells can also induce 
regeneration of tubular structures of different portions of the nephron, which can be critical 
for preventing irreversible renal failure, and could be useful in cell therapies, particularly in 
FAP. 
We have previously shown that EPO expression occurs in distal tubular cells, podocytes 
and cells of the cortical collecting ducts, in normoxic FAP patients [138]. Although there is 
no data regarding the ability of RPC to differentiate into EPO-producing cells, they can 
differentiate into podocytes and tubular cells, which could be important to maintain EPO 
production.  
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5. Oligomeric TTR V30M aggregates reduce erythropoietin mRNA expression 
 
The principal aim of this study was to evaluate the effects of oligomeric TTRV30M 
aggregates on EPO gene expression, in a cell culture model of EPO production. Due to 
the lack of an adequate renal EPO-producing cell line, we used the human hepatoma 
Hep3B cell line, described in 1987 by Goldberg et al. as a constitutive and inducible EPO 
producer, in an oxygen-dependent manner [273]. In a second phase, retinal pigment 
epithelial cells (RPE) were also evaluated for endogenous EPO gene expression. 
 
 
5.1. Oligomeric TTR V30M aggregates reduce EPO expression in Hep3B cells 
 
EPO mRNA expression in Hep3B cells exposed to 2 µM TTRV30M was evaluated by real-
time PCR. Threshold cycle (Ct) values obtained for EPO in normoxia were 32.68±0.08 for 
control media, 32.37±0.28 for tetrameric TTRV30M and 33.30±0.06 for oligomeric 
TTRV30M. In mimicking hypoxia using DMOG, a cell permeable panhydroxylase inhibitor, 
Ct values for EPO were significantly lower: 28.81±0.10 for control media, 28.58±0.40 for 
tetrameric TTRV30M and 28.37±0.13 for oligomeric TTRV30M. The housekeeping gene 
TBP was used as an internal control. Ct values for TBP did not differ significantly between 
samples (25.16±0.19). Relative quantification of EPO mRNA levels was calculated taking 
as reference a standard curve for EPO and the results were normalized to TBP, using a 
ΔCT model [286]. EPO expression after 24 hours was reduced by 50.3±2.8% (p=0,0092) 
in normoxic Hep3B cells treated with oligomeric TTRV30M when compared to the 
tetrameric form of the protein (figure 23A). 
With DMOG, EPO gene expression levels increased 13 to 22 times. In these simulated 
hypoxia experiments, cells did not show a significant difference in EPO expression levels 
using either tetrameric TTRV30M or oligomeric TTRV30M aggregates (figure 23B). 
 
Hep3B cells were also exposed to 2 µM tetrameric and oligomeric wild-type TTR for 24 
hours in normoxia. EPO expression was reduced by 22.0±9.1% (p=0,010) in Hep3B cells 
treated with oligomeric wild-type TTR when compared to the tetrameric form. 
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Figure 23 - Relative expression of erythropoietin in Hep3B cells exposed to TTR V30M for 
24 hours. (A) Relative expression levels of EPO, normalized for TBP, in normoxia. (B) 
Relative expression levels of EPO both in normoxia and simulated hypoxia (induced by 
DMOG). p value was calculated relatively to tetrameric TTR V30M experiments, using 
student’s t-test. *p<0,05. Values are means of duplicates. Error Bar= SD. 
 
 
The EPO gene has a hypoxia responsive element at the EPO 3’ enhancer site to which 
hypoxia inducible factor (HIF) can bind [287-289]. In normoxia, the α-chain of HIF is 
hydroxylated and degraded by the proteasome. In hypoxia the prolyl hydroxylases (PHD) 
and aspaginyl hydroxylase factor inhibiting HIF (FIH) are inhibited, the α-chain of HIF is 
not degraded and binds to the β-chain, which is constitutively expressed, and HIF 
accumulates, inducing gene expression [290-291]. To mimic hypoxia, we used the cell 
permeable panhydroxylase inhibitor dimethyloxalylglycine (DMOG). 
 
We found that exposure of normoxic Hep3B cells to oligomeric TTR V30M significantly 
reduces EPO mRNA expression. However, Hep3B cells treated with DMOG did not show 
significant differences in EPO mRNA levels when exposed to tetrameric or oligomeric TTR 
V30M. Under these simulated hypoxia conditions, Hep3B cells up-regulated EPO 
expression 13 to 20 times. It is possible that this large increase in EPO expression masks 
any effect of exposure to TTR aggregates on the gene expression level, or, alternatively, 
different regulatory mechanisms of EPO production could be involved in normoxia and 
hypoxia, altering the cellular response to the presence of oligomeric aggregates.  
Our previous work using patient kidney biopsies evaluated EPO expression in normoxia, 
and suggested that differences in the regulation of this gene in normoxia and hypoxia are 
Results and Discussion 
 
81 
 
possible [138]. Recently, Nagai et al. explored this subject and demonstrated that, in mice, 
EPO mRNA expression occurs in renal tubular cells in normoxia, as we have shown for 
the human ATTRV30M amyloidosis kidney, while in hypoxia it occurs largely in peritubular 
cells, strengthening the case for different regulatory mechanisms for EPO expression in 
normoxia and hypoxia [141]. 
 
Anemia in FAP patients sometimes precedes overt clinical disease and persists even after 
liver transplantation. There is evidence that after liver transplantation, the wild-type TTR 
can still form amyloid deposits and that there is progression and maybe even acceleration 
of amyloid deposition [59, 292]. In order to understand the persistence of low EPO 
production after liver transplantation, we produced oligomeric aggregates from normal 
TTR. We saw that Hep3B cells exposed to oligomeric wild-type TTR aggregates are also 
capable of reducing EPO mRNA expression when compared to tetrameric TTR controls. 
Although these studies were performed in vitro with a hepatoma cell line, they support the 
hypothesis that cytotoxic oligomeric species may be involved in the genesis of anemia in 
FAP patients. Besides this evidence, we recently showed that EPO concentrations in the 
aqueous humor of glaucomatous eyes of non-amyloidotic patients are significantly 
increased relatively to normal non-glaucomatous eyes, probably with a protective role 
[116]. However, in glaucomatous eyes of FAP ATTRV30M patients the EPO levels did not 
increase and maintained similar levels to those of control eyes [116]. These results show 
an inability of these patients to upregulate EPO production also locally in the retina. 
 
 
5.2. Oligomeric TTR V30M aggregates reduce EPO expression in RPE cells 
 
Beyond using Hep3B cells, a tumoral cell line, primary cell cultures of retinal pigment 
epithelial cells (RPE) were also evaluated for EPO gene expression. RPE cells when are 
cultivated acquire a hexagonal conformation and are pigmented (figure 24). As the cells 
divide, they gradually lose their pigment and start differentiating, acquiring a more 
elongated and fibroblast-like conformation (figures 25 and 26). Preliminary results showed 
that RPE isolated from the eye of an adult human cadaveric donor express EPO mRNA, 
but only on early passages (P0 and P1).  
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Figure 24 – Day 1 of a culture of retinal pigment epithelial cells (RPE) at passage 1 (P1), 
cultured on 25 cm3 flasks, visualized under light microscope with original magnifications 
x100 (A and B) and x200 (C-H). Note the abundance of pigment in the cytoplasm of these 
cells.  
 
 
 
Figure 25 – Day 3 (A) and day 8 (B and C) of a culture of retinal pigment epithelial cells 
(RPE) at passage 1 (P1), cultured on 25 cm3 flasks, visualized under light microscope with 
original magnifications x100 (A) and x200 (B-C). As the cells divide they start loosing their 
pigment.  
 
A        B       C                   D 
E           F           G                                  H 
A       B                 C 
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Figure 26 – RPE cells at passage 2 (P2), cultured on 25 cm3 flasks, visualized under light 
microscope with original magnifications x100. At this passage the cells lost most of their 
pigment and aquired a more fibroblast-like conformation.  
 
 
RPE cells on passage 1 were exposed to TTRV30M preparations. As already shown in 
sections 3.1. and 3.2., oligomeric TTRV30M aggregates reduced RPE cell viability with 
concomitant increase in caspase 3/7 activity. Real-time PCR showed that, similarly to 
what happened for Hep3B cells, EPO expression after 24 hours was reduced by 
48.3±17.1% (p= 7.0x10-3) in normoxic RPE cells treated with oligomeric TTRV30M when 
compared with tetrameric form experiments (figure 27).  
 
 
 
Figure 27 - Relative expression levels of erythropoietin in normoxic RPE cells exposed to 
TTRV30M for 24 hours. Values were normalized for TBP. p value was calculated relatively 
to tetrameric TTRV30M, using student’s t-test. *p<0,05 with respect to TTRV30M. Values 
are means of duplicates. Error Bar= SD. 
A        B     C 
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These are unpublished preliminary results. Further experiments are needed to validate 
these results and to better characterize this primary cell culture model, which responded 
to DMOG with a significant increase in EPO expression. As RPE cells are producers of 
both TTR and EPO in the eye, it may be a good model for a more detailed study of the 
mechanisms behind the inhibition of EPO production in FAP patients. 
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6. Oligomeric TTR V30M aggregates inhibit EPO promoter activity 
 
EPO gene expression is regulated at different levels: transcription, mRNA stabilization 
and at the translational level by an upstream open reading frame [160-163]. In hypoxia, 
HIF is the main regulator by binding to a hypoxia responsive element in the EPO 3’ 
enhancer and inducing EPO expression. In normoxia, GATA-2 and NF-kB inhibit EPO 
expression through proximal promoter binding sites.The transcription factors HIF, NF-kB 
and GATA-2 are key regulators of EPO gene expression [164-167].  
 
We saw that oligomeric TTR significantly reduces EPO mRNA expression in normoxic 
Hep3B cells. As in normoxia EPO expression is regulated mainly by NF-KB and GATA-2 
transcription factors, we constructed a reporter system containing a fragment of the EPO 
promoter sequence encompassing their binding sites.  
 
 
6.1. Transfection of Hep3B cells with Epo-Prom-pGL3 
 
The Epo-Prom-pGL3 reporter construct has recognition sites for the transcription factors 
GATA-2 and NF-kB in the cloned EPO promoter fragment. This reporter system was used 
to evaluate the influence of TTRV30M on the activity of the EPO promoter.  
Transfected Hep3B cells were exposed for 24 hours to different TTRV30M preparations. A 
significant reduction of the erythropoietin promoter activity (53.1±6.5%, p=0.0043) was 
observed in the cells exposed to oligomers when compared to cells exposed to the 
soluble tetrameric form of TTRV30M (Figure 28). No significant effect of tetrameric 
TTRV30M on the activity of the promoter was observed. 
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Figure 28 - Hep3B cells transfected with EPO Promoter (Epo-Prom-pGL3) and exposed to 
TTR V30M for 24 hours. Luminescence levels of Epo-Prom-pGL3 were normalized to 
Renilla luciferase plasmid pTK-RL. p value was calculated relatively to tetrameric TTR 
V30M, using the student’s t-test. *p<0,05 with respect to TTR V30M. Values are means of 
duplicates. Error bar = SD 
 
 
Inhibitory modulation of EPO gene expression by GATA-2 and NF-kB transcription factors, 
the main known negative regulators at the promoter level, has been demonstrated 
previously [166-168]. GATA-2 is activated by IL-1 and TNF-α, by exogenous and 
endogenous H2O2 and by L-NG-monomethylarginine (L-NMMA), a nitric oxide synthase 
(NOS) inhibitor that is markedly elevated in uremic patients, with consequent inhibition of 
EPO gene expression [168, 177-180]. NF-kB upregulation through RAGE, or upregulation 
of both NF-kB and GATA-2 mediated by oxidative stress and/or inflammatory signaling, 
are likely mechanisms for the reduction of EPO gene expression induced by oligomeric 
TTRV30M species. Evidences suggest that Hep3B cells express RAGE [293-294] and 
interaction of RAGE with transthyretin triggers NF-kB activation [251]. NF-kB may also 
inhibit EPO expression by inducing a transformation of the renal EPO-producing cells 
(REP) to myofibroflasts [181]. This phenotypic switch of REP cells to a pathological 
fibrogenic state is induced by inflammatory injury, and reverses when the inflammatory 
stimulus ceases.  
 
To explore the role of the EPO promoter in our model, a reporter assay system was 
constructed with a PCR fragment of the promoter linked to the luciferase gene. We saw a 
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reduction of EPO promoter activity in transfected Hep3B cells exposed to oligomeric 
species, parallel to the observed reduction in native EPO mRNA expression. These 
results suggest that downregulation of EPO expression in normoxic Hep3B cells exposed 
to oligomeric TTRV30M could be explained, at least in part, by a reduction of EPO 
promoter activity. As GATA-2 and NF-kB may repress EPO promoter activity, these 
transcription factors may be involved in the repression of EPO expression and promoter 
activity induced by the oligomeric TTR aggregates.  
 
 
6.2. Study of NF-kB and GATA-2 protein expression 
 
Immunofluorescence and immunohistochemistry were performed in order to explore the 
role of NF-kB and GATA-2. Hep3B cells were exposed to TTRV30M preparations for 24 
hours and immunofluorescence was performed for both NF-kB and GATA-2. No 
significant differences were observed between the oligomeric-treated and tetrameric-
treated cells. 
 
Immunohistochemistry for NF-KB and GATA-2 was performed on renal biopsies from FAP 
patients and from renal donors. As for immunofluorescence, no significant differences 
were observed between the renal FAP biopsies and the donors. Interestingly, GATA-2 
antibody cross-reacted with the amyloid deposits of the FAP renal biopsies and gave 
false-positive results.  
 
The influence of TTR aggregates on the activation of NF-kB and GATA-2 transcription 
factors still needs clarification. A technique such as chromatin immunoprecipitation (ChIP), 
followed by real-time pcr, may better elucidate if an interaction between one or both of 
these transcription factors with the EPO promoter is involved in the inhibition of EPO 
expression in FAP. 
 
A similar situation to that found in FAP patients, inappropriately low EPO production, also 
occurs in diabetic nephropathy (DN) [295]. Anemia occurs early in the course of DN due 
to either impaired production and/or response to EPO, even in the absence of renal 
impairment [295]. 
Diabetic nephropathy (DN) is a chronic disorder present in approximately 25%-40% of 
patients with long-standing diabetes. It is characterized by progressive albuminuria and a 
decline in renal function [296]. Chronic elevated blood glucose together with glomerular 
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hypertension leads to renal inflammation, progressive glomerulosclerosis and 
tubulointerstitial fibrosis resulting in organ failure.  
Among the key modulators implicated in the pathogenesis of DN, which adversely affect 
the response to anemia, are oxidative stress and overproduction of reactive oxygen 
species (ROS), activation of protein kinase C and mitogen-activated protein kinase 
(MAPK) signaling pathways, production of advanced glycation end products (AGEs) and 
activation of the receptor for advanged glycation end products (RAGE) and upregulation 
of the nuclear factor-κB (NF-κB) [155, 295-297]. In particular, there is excess 
accumulation and exposure of the kidney to AGEs [298]. AGE may activate downstream 
targets such as cytokines and growth factors: monocyte chemo attractant protein (MCP-
1), transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF) and 
vascular endothelial growth factor (VEGF) that may be involved in the development and 
progression of DN. The upregulation of NF-κB may influence EPO production, as this 
transcription factor suppresses EPO expression [168].  
Evidences suggest that, in pre-symptomatic FAP patients, the presence of early non-
fibrillar TTR aggregates induces the expression of oxidative stress, apoptosis related 
molecules and pro-inflammatory cytokines, via interaction with RAGE and activation of 
NF-kB. A common mechanism that explains the inhibition of EPO production may be 
involved in both pathologies, FAP and DN, which may be related to the activation of 
RAGE.  
 
 
6.3. Co-transfection of Hep3B cells with Epo-Prom-pGL3 and pCG-ATF3 
 
Activating transcription factor 3 (AFT3) is a member of the ATF/cAMP responsive element 
binding protein (ATF/CREB) family. ATF3 is rapidly induced upon exposure of cells to 
stress signals, such as ischemia, wounding, toxicity, seizures, serum factors, cytokines, 
genotoxic and cell death-inducing agents [183, 299].  
Although ATF3 is not classically described as a regulator of EPO expression, it is involved 
in the activation of EPO promoter in stromal cells in response to the platelet-derived 
growth factor (PDGF) signaling system [182]. Besides, overexpression of ATF3 alone led 
to a substantial increase in EPO promoter activity, although not as potent as PDGF-BB 
treatment [182].  
The role of ATF3 was explored in our model of EPO expression. Hep3B cells were co-
transfected with both the Epo-Prom-pGL3 reporter construct and with an ATF3 expression 
plasmid (pCG-ATF3). This ATF3 plasmid was kindly donated by Professor Tsonwin Hai 
and is well characterized [300].  
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Using Hep3B cells transfected with the Epo-Prom-pGL3 reporter construct, it was shown 
previously that oligomeric TTRV30M aggregates reduced approximately 2-fold the activity 
of EPO promoter relatively to the tetrameric-treated cells. The overexpression of ATF3 in 
Hep3B cells co-transfected with the Epo-Prom-pGL3 reporter construct and ATF3 vector 
led to an increase of the promoter activity in oligomeric-treated cells to a similar value to 
that observed in tetrameric TTR-treated cells (figure 29). 
 
 
 
Figure 29 - Hep3B cells co-transfected with EPO Promoter (Epo-Prom-pGL3) and pCG-
ATF3, an expression vector containing the ATF3 gene. Cells were exposed to TTR V30M 
for 24 hours. Luminescence levels of Epo-Prom-pGL3 were normalized to Renilla 
luciferase plasmid pTK-RL. Error bar = SD 
 
 
The inhibitory effect induced by TTR oligomers on EPO promoter activity seems to be 
reversed by the expression of ATF3. These results are preliminary and require further 
study, but raise the possibly that ATF3 alone, or together with other transcription factors, 
participates in the regulation of EPO gene expression. 
 
It is known that ATF3 is involved in the regulation of several genes, not necessarily via 
direct binding to the promoter of the target gene, but forming complexes with other 
transcription factors or cofactors [301]. It may stabilize the co-factors at the promoter or 
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sequester them away from the transcription machinery, resulting in transcriptional 
regulation [182-183, 299-302]. 
Xue et al propose that the formation of a complex between the ATF3, c-Jun and Sp1 
explains the increase of EPO promoter activity induced by PDGF-BB [182]. They showed 
that the EPO promoter region does not contain an ATF3 binding site, suggesting that 
ATF3 may not act directly on the EPO promoter [182]. Elevated expression of PDGF has 
been observed in RPE cells after retinal detachments or retinal laser treatment in murine 
model systems [184], in in vitro wounded human RPE cell cultures [185] and in epi-retinal 
membranes isolated from proliferative vitreoretinopathy and proliferative diabetic 
retinopathy patients [186].  
Besides Sp1 and c-Jun, ATF3 may also interact with NF-kB, p53 and p73. It may also 
inhibit transcription of pro-inflammatory cytokines, by interacting with NF-κB at the 
promoter of these target genes [301].  
 
In our TTRV30M exposure Hep3B cell model, it appears that oligomeric TTRV30M 
aggregates inhibit EPO expression by decreasing EPO promoter activity. However, when 
the cells over-express ATF3 the inhibitory effect of these aggregates is reverved. This 
could be due either to increased activity of promoter inhibitors or to a decreased activity of 
ATF3, preventing it from sequestering these inhibitors away from the EPO promoter. This 
issue deserves further study. 
 
ATF3 has a basic region-leucine zipper (bZip) DNA binding domain. However, several 
isoforms derived from alternative splicing have been described (ATF3ΔZip, ATF3ΔZip2a, 
ATF3ΔZip2b, ATF3ΔZip2c, ATF3ΔZip3, and ATF3b), lacking the leucine zipper region 
[302]. The role of these alternative splicing forms needs also to be explored.  
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Conclusions and Future Perspectives 
 
In this project we carried out in vitro studies aiming to explore the role of amyloid 
deposition in ATTRV30M amyloidosis, especially regarding the role of early non-fibrillar 
aggregates on cell differentiation and erythropoietin production. 
 
First, the production of recombinant human TTRV30M and their oligomeric aggregates 
were optimized. Obtaining a pure and LPS-free protein for the cellular assays was crucial 
to ensure that the effects on the cells were only due to the protein preparations.  
The poor reproducibility of preparation of cytotoxic oligomeric solutions made it necessary 
to test several methods described in the literature, for optimization. Mild acidification (pH 4 
to 5.5) of the protein solution, acidification to pH 2.0 followed by NaCl or aging under 
physiological pH and temperature followed by vigorous stirring were the methods chosen. 
In the case of acidification to mild pH we obtained insoluble material, probably amorphous 
aggregates that, despite being positive in ThT assays, were not toxic to cells. The method 
that induced the formation of most cytotoxic species and with the most reproducible 
results was the last one tested, aging the protein at physiological pH and 37ºC for 72 
hours followed by 5 minutes of stirring. This TTR preparation contained mainly oligomers 
of approximately 300 nm when analysed by dynamic light scattering, and was the one 
used for the subsequent cell culture assays. 
 
Different cell culture models were used to evaluate the influence of oligomeric TTR 
aggregates on cell viability: using immortalized human hepatoblastoma Hep3B, 
neuroblastoma SH-SY5Y and embryonic kidney cells HEK293T, as well as primary retinal 
pigment epithelial cells RPE and human renal progenitor cells RPC. The proliferation of 
the cells exposed for 24 hours to oligomeric TTRV30M aggregates was moderately 
reduced when compared to the cells exposed to the tetrameric protein, independently of 
the cell type. Oligomers generated from the wild-type TTR also reduced cell proliferation 
in comparison to the soluble tetrameric form. Both oligomeric TTR and TTRV30M 
preparations were cytotoxic, a process that may be common to all prefibrillar amyloid 
protein aggregates. 
Concomitantly to the reduction in cell proliferation, a significant increase in caspases 3/7 
activity occurred in cells exposed to oligomeric TTRV30M aggregates, implicating 
apoptosis in the loss of viability. These results are in agreement with other studies 
performed mainly in neuronal cells (neuroblastoma) [106, 229, 250, 270-272]. 
Interestingly, the cytotoxic effect induced by the aggregates seems to be independent of 
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the cell type, since both immortalized, as well as primary and progenitor cells were shown 
to be susceptible to damage and apoptosis driven by aggregate exposure.  
 
Renal progenitor cells (RPC) express the stem cell markers CD133+CD24+ and may 
potentially differentiate into podocytes and tubular cells. We evaluated the influence of the 
oligomeric aggregates on the viability and differentiation capacity of the RPC, in order to 
understand if the misfolded protein could compromise a potential therapeutic use of these 
cells to treat renal damage. Proliferation of RPC in vitro was impared by the oligomeric 
TTRV30M aggregates comparatively to the tetrameric form, but their differentiation 
capacity into mature podocytes was not significantly affected, so renal tissue regeneration 
should not be compromised by the presence of early oligomeric species.  
 
ATTRV30M amyloidosis patients develop anemia with low EPO levels. The impaired EPO 
production is not related to the extent or pattern of congophilic renal deposition or with the 
presence of circulating mutant TTRV30M. The role of oligomeric aggregate cytotoxicity on 
EPO production had not been studied yet.  
In this work we used the EPO producing cell line Hep3B to evaluate the influence of 
oligomeric TTRV30M aggregates on EPO gene expression, as well as on pathways linked 
to the regulatory regions of the EPO gene. Normoxic Hep3B exposed for 24 hours to early 
oligomeric TTRV30M aggregates showed a 2-fold reduction in EPO mRNA expression. In 
accordance to this reduction, there was a 2-fold reduction in EPO promoter activity in 
transfected Hep3B cells. These results support involvement of early oligomeric TTR 
aggregates in decreased EPO gene expression and could explain the anemia and low 
EPO levels in FAP patients, seen even in the pre-symptomatic phase of the disease. 
Interestingly, a preparation of wild-type TTR oligomers also reduced EPO mRNA 
expression in normoxia, although to a less extent than the TTRV30M oligomers, which 
may explain the continuing low EPO production after liver transplantation seen in FAP 
patients.  
The inhibition of EPO expression caused by exposure of the cells to cytotoxic oligomeric 
aggregates seems to be mediated by decreased activity of the EPO promoter. 
Transcription factors such as NF-kB and GATA-2 bind to the promoter and inhibit 
transcription of the EPO gene, mainly in inflammatory states. Here, we obtained 
inconclusive results about the influence of oligomeric aggregates on NF-kB or GATA-2 
activation. However, we believe this issue deserves further consideration, as well as other 
signaling pathways that may be activated by the oligomeric species and that may 
influence EPO expression.  
 
Conclusion and Future Perspectives 
 
95 
 
FAP patients are also unable to up-regulate EPO production in the glaucomatous eye, as 
a neuroprotective response. Besides the possible involvement of TTR aggregates in EPO 
expression and anemia, a much wider role for these aggregates in disease progression 
could be considered. Recent studies point to a potentially major role of EPO in 
neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, 
epilepsy, multiple sclerosis and motor neuron diseases [151, 303-311]. It has been 
already shown in another model of amyloid-related neurodegeneration, in which PC12 
cells are exposed to Aβ25-35 aggregates, that apoptosis is counteracted by EPO signaling 
[312-313]. EPO has also been found to increase the resistance of neurons to damage 
induced by pro-inflammatory agents [314]. It could be postulated that deposition of TTR 
aggregates in the peripheral nervous system down-regulates local EPO expression, 
depriving neurons from needed neuroprotective signals, contributing thus for the onset 
and/or progression of the disease, an hypothesis that we feel deserves further study. 
 
Retinal pigment epithelial cells (RPE) produce both EPO and TTR in the eye. In order to 
find a more suitable cell culture model to explore the direct effect of the amyloidogenic 
TTRV30M on EPO production, we isolated RPE cells from an eye of a human cadaveric 
donor. Preliminary results showed that, at early passages, these cells express EPO in 
normoxia and respond to hypoxia simulated with DMOG.  
Besides the reduction of cell proliferation and increased activity of caspases 3/7, EPO 
gene expression in normoxic RPE treated for 24 hours with oligomeric TTRV30M 
aggregates was reduced by approximately 2-fold comparatively to the cells exposed to 
tetrameric TTRV30M, similarly to what was seen in Hep3B cells. This is an important 
result as it shows a direct influence of the oligomeric species on a primary cell line that is 
physiologically responsible for EPO production in the eye.  
 
As future perspectives, and taking into consideration these preliminary results, we believe 
that RPE cells could become a suitable cell culture model to further explore the 
mechanisms responsible for EPO inhibition in ATTRV30M amyloidosis, ideally, using RPE 
cells from FAP patients.  
 
The blockage of EPO production observed both in the kidney as in the eye of FAP 
patients also happens in Diabetic Nephropathy (DN). Oxidative stress, overproduction of 
reactive oxygen species (ROS), production of AGEs, activation of the receptor for 
advanged glycation end products (RAGE), upregulation of the NF-κB and pro-
inflammatory cytokines seem to be common factors between FAP and DN. ROS may 
upregulate GATA-2. In this work we used immunofluorescence to study the activation of 
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NF-kB and GATA-2 by exposure to oligomeric aggregates and we could not see 
significant differences. However, it would be important to use more sensitive techniques, 
such as Chromatin immunoprecipitation or electrophoretic mobility shift assays (EMSA), 
which can show protein-DNA interaction, to confirm if the inhibition of EPO expression by 
cytotoxic aggregates is indeed related to activation of these two transcription factors. 
ATF3 is other transcription factor that may be involved in EPO gene regulation. In our cell 
model, the over-expression of ATF3 reversed the inhibitory effect of the oligomeric TTR 
aggregates on the EPO promoter activity. This is a preliminary observation that deserves 
further study. It would also be interesting to use DN patients for comparison.  
 
Tafamidis is a drug already approved for the treatment of eligible FAP patients. We would 
like to know if Tafamidis, a TTR tetramer stabilizer, is able to prevent blockage of EPO 
production. 
 
In summary, although we have shown here that exposure to cytotoxic oligomeric TTR 
aggregates inhibits EPO expression in vitro, much remains to be discovered about the 
mechanisms underlying this inhibition and possible therapeutic targets. 
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Annex 
Papers published by the author of this thesis during the PhD, that have 
not been used on the results section, but are in the context of theme 
developed here 
  
 
Glaucoma is a progressive optic nerve neuropathy and 
the major cause of preventable and irreversible blindness 
worldwide. It is characterized by visual field defects and 
nerve head cupping due to the loss of retinal ganglion cells 
[1]. Despite its multifactorial genesis [2-4], the major risk 
factor for glaucoma progression is the elevated intraocular 
pressure (IOP) [5,6], which compresses the retinal ganglion 
cells at the optic nerve head [7]. The only treatment that slows 
glaucoma progression involves lowering the IOP [8].
Familial amyloid polyneuropathy (FAP) is caused by the 
extracellular deposition of amyloid fibrils of mutant trans-
thyretin (TTR) V30M in various tissues and organs [9-11]. 
TTR V30M mutation is the most common form of trans-
thyretin amyloidosis (ATTR) variant in Portugal as well as 
in the world [12]. The main clinical expression of FAP disease 
is a sensorimotor and autonomic neuropathy, but other mani-
festations, such as nephropathy and hematologic and ocular 
abnormalities can occur. Among the reported ocular FAP 
complications [13-15], glaucoma is the major cause of irre-
versible vision loss and is often difficult to control [16].
Erythropoietin (EPO) was identified as a hematopoietic 
cytokine that promotes proerythroblast survival and matura-
tion [17]. Recently, EPO was recognized as a member of the 
cytokine type 1 superfamily with multiple functions outside 
the bone marrow [18]. It provides direct protection against 
hypoxia by its anti-apoptotic, anti-oxidative, and anti-inflam-
matory properties and for its angiogenic capacity that allows 
the oxygen supply to ischemic tissues. Several studies have 
found that EPO protects photoreceptor cells, retinal ganglion 
cells, and retinal pigment epithelial cells from apoptosis 
[19-26]. Hernandez et al. [27] suggested that EPO is produced 
locally in the retina. Muller cells and retinal pigment epithe-
lium were identified by Fu et al. [28] and Garcia-Ramírez et 
al. [29], respectively, as the cells responsible for EPO produc-
tion in the eye.
Previous studies have shown a significantly increased 
EPO concentration in the aqueous humor of eyes with glau-
coma [30-32]; this is probably a defence mechanism against 
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Aqueous humor erythropoietin levels in open-angle glaucoma 
patients with and without TTR V30M familial amyloid 
polyneuropathy
João M. Beirão,1,2,3 Luciana M. Moreira,3,4 João C. Oliveira,5 Maria J. Menéres,1,3 Bernardete B. Pessoa,1 
Maria E. Matos,3 Paulo P. Costa,3,4 Paulo A. Torres,1,3 Idalina B. Beirão2,3
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Purpose: Glaucoma is the leading cause of irreversible blindness in familial amyloidotic polyneuropathy (FAP) patients. 
Erythropoietin (EPO) is a cytokine that has been shown to play a role in neuroprotection and is endogenously produced 
in the eye. EPO levels in the aqueous humor are increased in eyes with glaucoma. In this study, we evaluated the EPO 
concentration in the aqueous humor of FAP and non-FAP patients, with and without glaucoma.
Methods: Undiluted aqueous humor samples were obtained from 42 eyes that underwent glaucoma surgery, phacoemul-
sification, or vitrectomy. EPO concentration in the aqueous humor and blood were measured using the Immulite 2000 
Xpi using an automatic analyzer (Siemens Healthcare Diagnostics).
Results: The mean EPO concentration in the aqueous humor of non-FAP glaucoma eyes group 2 (75.73±13.25 mU/ml) 
was significantly higher than non-FAP cataract eyes (17.22±5.33 mU/ml; p<0.001), FAP glaucoma eyes (18.82±10.16 
mU/ml; p<0.001), and FAP nonglaucoma eyes (20.62±6.22 mU/ml; p<0.001). There was no statistically significant 
difference between FAP nonglaucoma eyes versus non-FAP cataract eyes (p = 0.23) and FAP glaucoma eyes versus 
FAP nonglaucoma eyes (p = 0.29). In the glaucoma groups, there was no correlation between the aqueous humor EPO 
concentration and the ocular pressure (p = 0.95) and mean deviation (p = 0.41). There was no correlation between the 
EPO serum concentration and EPO aqueous humor concentration in our patients (p = 0.77).
Conclusions: Unlike other glaucomatous patients, FAP patients with glaucoma do not show increased and potentially 
neuroprotective endocular EPO production in the aqueous humor and may need more aggressive glaucoma management.
Correspondence to: Melo Beirão, Serviço de Oftalmologia, Hospital 
de Santo António, Largo Prof. Abel Salazar, 2, 4099-001 Porto, 
Portugal; Phone: +351966009826; FAX: + 351 22 606 61 06; email: 
bbeirao@iol.pt
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glaucomatous damage [33] caused by hypoxia, ischemia, 
oxidative stress, and reduced pro-inflammatory cytokine 
production [34-39]. Although hypoxia/ischemia is the major 
stimulus for endocular and systemic EPO production [21,40-
43], other incompletely understood factors may be involved 
[27,29].
FAP patients and even presymptomatic carriers have an 
inappropriately low EPO production [44]. In vitro studies 
suggest that the dissociated mutant TTR that polymerizes into 
misfolding amyloidogenic intermediates, protofilaments, and 
nonfibrillar aggregates of TTR rather than mature amyloid 
fibrils may induce cellular toxicity [45,46]. We propose that 
these amyloid precursors may be toxic to EPO-producing 
cells. This study was performed to evaluate the ocular EPO 
response in FAP patients with glaucoma.
METHODS
It was recruited 42 eyes of 42 patients (18 females) with a 
mean age of 56.8±7.4 years. A prospective, controlled, 
nonrandomized, nonblind comparative study was conducted 
from January 2008 to December 2011 at the Ophthalmic and 
Clinical Chemistry Departments from Centro Hospitalar do 
Porto, Porto. Written informed consent was obtained from 
all patients. This study was performed in accordance with 
the Declaration of Helsinki of the World Medical Association 
and was approved by the Ethics Committee of the Centro 
Hospitalar do Porto.
Presurgical assessment included Snellen best-corrected 
visual acuity (Snellen chart, Takagi chart projector CP-30, 
calibrated for approximately 6 m), slit-lamp biomicroscopy, 
intraocular pressure (IOP) measurement by Goldman appla-
nation tonometry (same person with AT-900 tonometer; 
Haag-Streit, Koniz, Switzerland), fundoscopy (90 D noncon-
tact slit-lamp lens; Volk Optical, Mentor, OH), Humphrey 
perimetry (Humphrey Field Analyzer; Humphrey Instru-
ments, San Leandro, CA), and the cup/disc ratio. All exami-
nations were performed within 2 weeks before the surgical 
procedure.
Exclusion criteria for all groups were: previous laser 
and/or intraocular surgery; history of systemic (e.g., diabetes 
mellitus, kidney disease, cardiovascular disorders, anemia, 
immune disease, except FAP in groups 1 and 3) or any ocular 
disorders (e.g., age-related macular degeneration); history 
of medications that could influence the level of EPO (e.g., 
iron preparations, chemotherapeutic agents, granulocyte 
colony-stimulating factor, or systemic therapy with EPO), and 
patients with any type of glaucoma except open-angle glau-
coma, such as angle-closure, pigmented, exfoliation, normo-
tensive, and neovascular glaucomas, or ocular hypertension.
To clarify the relationship between aqueous EPO produc-
tion and circulating blood EPO levels, we compared the 
aqueous and serum concentrations of EPO. Aqueous humor 
samples were obtained from each eye before the beginning 
of surgery (trabeculectomy, phacoemulsification, or vitrec-
tomy). The standard procedure involved collecting undiluted 
aqueous humor samples (50–150 µl) through a paracentesis, 
using a 30-gauge needle on a tuberculin syringe under an 
operating microscope. Samples were obtained carefully to 
avoid touching intraocular tissues or blood contamination. 
All samples were carefully protected from light and were sent 
immediately to the laboratory for EPO measurement. At the 
same time, 9 ml of venous blood samples were collected in 
EDTA tubes  from an antecubital vein immediately before 
sugery. The blood was immediately centrifuged and the blood 
serum put on the automatic analyzer.
Serum samples were obtained from the centrifugation of 
the blood sample. The samples of aqueous humor and serum 
had the same processing routine analysis. Serum and aqueous 
humor EPO concentrations were measured by a chemilumi-
nescent method in an automatic Xpi Immulite 2000 analyzer 
(Siemens Healthcare Diagnostics, Siemens AG, Munich, 
Germany).
Statistical analysis: Statistical analysis was performed using 
nonparametric tests. The Kruskal–Wallis test was used to 
compare the groups in relation to age, and the chi-square test 
was used in relation to gender. The Mann–Whitney U test 
was used to compare the nonglaucoma, glaucoma, and FAP 
groups in relation to aqueous humor EPO and serum EPO 
levels. The relation between EPO and serum was evaluated 
by Spearman correlation. Values of p<0.05 were considered 
statistically significant. Data analysis was performed using 
IBM SPSS Statistics software version 20.
RESULTS
A total of 21 glaucomatous eyes from 21 patients and 21 
control eyes (21 patients) were enrolled in the study. The 
demographic characteristics of the patients are summarized 
in Table 1. Of the glaucoma eyes, ten were from FAP patients 
(group 1, mean age 55.4±10.0  years mean and standard devia-
tion; five females) and 11 were from non-FAP patients (group 
2, mean age 55.8±7.0 years mean and standard deviation; four 
females). Of the 21 control eyes, nine were from FAP patients 
with an indication for vitrectomy due to amyloid deposition 
(group 3, 55.9±8.5 years mean and standard deviation; four 
females) and 12 were from non-FAP patients awaiting phaco-
emulsification and intraocular lens implantation (group 4, 
58.8±4.9 years mean and standard deviation; five females). 
Groups 1 and 2 presented indications for trabeculectomy, 
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had uncontrolled IOP (defined as IOP higher than the target 
pressure with maximally topical antiglaucoma medications: 
prostaglandin + beta blocker + anhydrase carbonic inhibitor 
+ alpha-2 agonist), abnormal visual field test results, and 
abnormal cup/disc ratio.
The ages and gender distribution of the patients were 
similar between groups (Kruskal–Wallis test, p = 0.56; 
chi-square test, p = 0.94). All FAP patients had received an 
orthotopic liver transplant.
As summarized in Table 2, the mean EPO concentra-
tion in the aqueous humor of nonglaucomatous eyes (group 
3 versus group 4) was not significantly different between 
FAP and non-FAP patients (20.62±6.22 mU/ml in group 3 
and 17.22±5.33 mU/ml in group 4, p = 0.23) and corresponds 
presumably to the basal ocular production of EPO. In the pres-
ence of glaucoma, EPO concentrations in the aqueous humor 
showed a significant increase in the non-FAP group (group 2, 
75.73±13.25 mU/ml; group 1, 18.82±10.16 mU/ml; p<0.001), 
and when we compared the non-FAP glaucoma group (group 
2) with the nonglaucoma groups (FAP group 3 and non-FAP 
group 4), a similar finding was observed (p<0.001) (Table 
2). In the FAP groups (group 1 and group 3), we observed 
no significant difference between the mean EPO values  of 
patients with or without uncontrolled glaucoma (p = 0.29). As 
listed in Table 3, FAP patients with glaucoma (group 1) and 
non-FAP patients with glaucoma (group 2) were comparable 
in terms of the IOP (p = 0.39) and mean deviation (p = 0.75). 
The correlation between the IOP and the aqueous humor EPO 
was not significant in group 1 (mean IOP 26.20±1.93 mmHg; 
rs = 0.02, p = 0.95) and group 2 (mean IOP 26.82±1.72 mmHg; 
rs = 0.27, p = 0.41). There was also no significant correlation 
between the mean deviation and the aqueous humor EPO in 
group 1 (rs = –0.48, p = 0.16) or group 2 (rs = –0.07, p = 0.83).
Serum EPO levels among patient groups were not 
significantly different when multiple testing was taken into 
account (Bonferroni correction). No statistically significant 
correlation between the values  of EPO in the serum and in 
the aqueous humor was observed in any patient (Spearman 
correlation coefficient r = 0.047, p = 0.77).
Table 1. Demographic of The groups.
Age/Sex Group 1 FAP glaucoma
Group 2 Non-FAP 
glaucoma
Group 3 FAP 
non-glaucoma
Group 4 Non-FAP 
non-glaucoma
Age (year, 
mean±SD) 55.4±10.0 55.8±7.0 55.9±8.5 58.8±4.9
Female/Male 5 / 5 4 / 7 4 / 5 5 / 7
Table 2. epo in aqueous humor anD serum of The groups.
Aqueous humor/
serum EPO level
Group 1 FAP 
glaucoma
Group 
2 Non-FAP 
glaucoma
Group 3 FAP 
non-glaucoma
Group 4 Non-FAP 
non-glaucoma
Aqueous humor 
EPO level (mU/ml) 18.82±10.16 75.73±13.25 20.62±6.22 17.22±5.33
Serum EPO level 
(mU/ml) 13.44±4.82 9.99±2.84 15.04±5.87 8.73±4.12
Aqueous humor EPO (Mann–Whitney U test): Group 3 versus Group 4 p=0.23 ; Group 1 versus Group 2 
p<0.001; Group 1 versus Group 3 p=0.29; Group 2 versus Group 4 p<0.001
Table 3. inTraocular pressure anD mean DeviaTion in glaucoma groups.
IOP/mean deviation Group 1 FAP Glaucoma
Group 2 Non FAP 
Glaucoma
P value Mann–
Whitney test
N 10 11
IOP, mmHg, mean±SD 26.20±1.93 26.82±1.72 0.39
Mean deviation, dB, 
mean±SD −8.92±3.30 −8.26±3.63 0.75
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DISCUSSION
Glaucoma is a manifestation of a heterogeneous group of 
diseases with a very complex and multifactorial pathophysi-
ology [8]. Although hypotensive therapy is today the only 
possible therapeutic intervention, neuroprotective treatment 
strategies are emerging as a result of the advances in the 
comprehension of the pathophysiological mechanisms of 
glaucoma. In the future, neuroprotective agents will probably 
be part of the therapeutic arsenal available for the treatment 
of glaucoma. EPO has been shown to have a protective effect 
on ganglion cells against acute ischemia injury [28,47] and 
has been proposed as a potential neuroprotective treatment.
In this study we confirmed that the aqueous humor EPO 
level is higher in glaucomatous eyes than in nonglaucomatous 
eyes with cataracts, as previously reported [30-32,48,49]. This 
increase in aqueous humor EPO levels could be a result of 
local production and/or active transport through the blood–
ocular barrier. This observation lends support to the hypoth-
esis that EPO acts as an endogenous neuroprotector of retinal 
ganglion cells [19].
In spite of the inappropriately low renal EPO produc-
tion reported in FAP ATTR V30M [44], its basal level in the 
aqueous humor of FAP patients was not significantly altered. 
However, FAP patients seemed to be unable to increase 
endocular EPO production in the presence of glaucoma. In 
previous studies, we showed an inappropriate secretion of 
renal EPO in FAP and an inability to increase EPO produc-
tion in response to decreased serum hemoglobin levels, 
leading to a high incidence of anemia in these patients. The 
lack of response to glaucoma in FAP patients could be the 
ocular counterpart of the stunted renal EPO production in 
FAP in response to anemia.
It has been suggested that inhibition of EPO production 
could be caused by the toxicity of prefibrillar aggregates of 
TTR V30M [44,50,51]. These oligomers induce the expres-
sion of oxidative stress, pro-inflammatory cytokines, and 
apoptosis-related molecules [52,53] through the binding 
of TTR aggregates to the receptor for advanced glycation 
end products, activation of extracellular signal-regulated 
kinase cascades, and nuclear transcription factor kB [52-56], 
suppressing the EPO production. All our FAP patients had 
previously received an orthotopic liver transplant to elimi-
nate their main source of mutant TTR, their own liver [57]. 
After liver transplantation, mutant TTR is removed from 
systemic circulation; however, its local production in the 
eye remains presumably unaffected. Therefore, the ocular 
pathology related to FAP, which includes glaucoma, continues 
to progress after liver transplantation; presumably there is 
also continuing deposition of cytotoxic prefibrillar TTR 
aggregates.
Garcia-Ramirez found that other factors besides hypoxia-
inducible factors (HIF)-mediated hypoxia might be important 
in the upregulation of EPO. Hypoxia, ischemia, elevated 
reactive oxygen species, or increases in glutamate and nitric 
oxide caused by glaucomatous damage are probably the cause 
of elevated aqueous humor EPO concentration in chronic 
glaucoma [30]. The pro-inflammatory cytokines interleukin 
(IL)-1, IL-6, interferon-γ, and tumor necrosis factor (TNF)-α 
inhibit EPO production [58,59], but despite being increased in 
the aqueous humor of glaucoma eyes, as is especially the case 
for TNF-α [60], these cytokines do not prevent an increase in 
EPO levels.
Increased levels of TTR in the aqueous humor of glau-
coma patients have been documented [61-63]. If glaucoma 
leads to an increase expression of TTR in the aqueous 
humor, an increased concentration of the unstable TTR 
V30M in FAP patients’ eyes could contribute to the increased 
development of a mechanical barrier to the outflow of the 
aqueous humor [64], resulting in worsening the glaucoma. 
The association of open-angle glaucoma with autonomic 
nervous system dysfunction suggests that this could also 
play a role in the pathogenesis of the disease [65]. Patients 
with systemic sympathetic and parasympathetic neuropathies 
have a higher incidence of open-angle and normal-pressure 
glaucoma [66-69]. Because FAP patients have an early onset 
neuropathy with markedly autonomic involvement, it is 
likely that autonomic dysfunction plays a role in glaucoma 
pathophysiology. Other possible contributing factors are the 
hemodynamic instability often presented in FAP patients due 
to vascular deregulation and abnormal blood pressure that 
may compound the harmful effects of glaucoma, particularly 
during sleep [65].
In the groups with glaucoma, there was no correlation 
between the aqueous humor EPO concentration and the values 
of IOP and mean deviation. It seems that the concentration of 
EPO in the aqueous humor is not related to the IOP in eyes 
with glaucoma or previous eye injury caused by glaucoma.
In this study, patients with pseudoexfoliative and uveitic 
glaucomas were excluded because some studies pointed to 
blood–aqueous humor barrier breakdown in these situations 
[70,71]. EPO can cross the blood–brain barrier and blood–
retina barrier [41]. We did not found a significant correlation 
between aqueous humor and serum EPO concentrations as 
other authors have found [30,31]. The elevation of the aqueous 
humor EPO level in glaucoma was not associated with a 
parallel increase in blood EPO levels, corroborating the role 
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of local EPO production as already proposed by Fu [28] and 
Garcia-Ramirez [29].
In conclusion, our study confirmed that the level of 
EPO is increased in aqueous humor of open-angle glauco-
matous eyes, as found by other authors. This increase was 
not observed in FAP patients. With the increased survival of 
transplanted FAP patients, glaucoma prevalence is expected 
to increase dramatically with increased suvival of the trans-
planted patients. We showed lower endogenous neuroprotec-
tion in glaucomatous eyes of FAP patients, emphasizing the 
need for more aggressive glaucoma management to maintain 
vision through life.
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Use of MALDI-TOF Mass Spectrometry to Assay
the Transthyretin V30MMutation in Serum From a
Liver Transplant Donor: A Case Report
Pedro Castro Lacerda,1 Luciana Moreira,1,2 Rui Vitorino,3 Paulo Pinho Costa1,2
Familial amyloidotic polyneuropathy (FAP), Portuguesetype, or ATTR V30M is an autosomal dominant in-
herited disorder caused by a mutation in the transthyretin gene,
with a valine/methionine substitutionat position30 (TTRV30M).1
ATTRV30Mischaracterizedbyaprogressivesensory/autonomic
polyneuropathy and multiple organ dysfunction.2
Liver transplantation is the main therapeutic option,3 as
it virtually eliminates the production of circulating TTR
V30M, which occurs predominantly in the liver.
CASE REPORT
In 2004, a then 35-year-old female FAP patient underwent
orthotopic liver transplantation from a cadaveric donor to
treat her condition. Progression of FAP after liver transplan-
tation has been documented but usually stabilizes after some
time.4 Continuing deterioration in this patient raised the sus-
picion, confirmed in 2012, that the liver donor was also a
TTR V30M carrier. Retransplantation was proposed and
carried out, but these unfortunate circumstances made it nec-
essary to assure the anxious patient, and the transplantation
center for that matter, that this second time the transplanted
liver was FAP free.
Serum from the second cadaveric transplant donor was
sent to us, a few days after the procedure, and absence of
TTRV30M was established by immunoprecipitation of
TTR followed by mass spectrometry analysis.5 The spectra
that comprise the molecular mass of TTRmonomers are rep-
resented inF1 Figure 1. In the positive control sample
(Figure 1C), we identified 3 peaks that correspond, respec-
tively, to the free form of wild type TTR (13.708 ± 10 Da),
the cysteine (Cys) conjugated form of the wild type TTR
(13.824 ± 10 Da), and the cysteine conjugated form of the
TTR V30M variant (13.860 ± 10 Da), with a difference of
approximately 33 Da from the wild type TTR.5 The liver
transplant donor sample (Figure 1A) showed the 2 peaks
attributed to wild type TTR only (13.694 ± 10 and
13.816 ± 10 Da) as seen in the negative control (Figure 1B).
DISCUSSION
Domino FAP liver transplantation into non-FAP patients
is common in some centers. In these cases, TTRV30M pro-
duction has been found to be followed by FAP symptoms as
soon as 7 years after transplantation.6When this happens, re-
transplantation is usually proposed. In areas with a high
prevalence of FAP, like the north of Portugal (1:550),7 there
is a non-negligible risk of a FAP patient receiving a liver from
an untested FAP donor. Portuguese law assumes that every
citizenwho does not declare otherwise is an organ donor. Un-
fortunately, reliable individual clinical information is usually
not available. Familial amyloidotic polyneuropathy is a late-
onset disease, and predictive testing, even if done, is not to be
found in clinical records, by force of law. So, at the time of
transplantation, up to 12 hours after liver collection, there
is usually no other information on personal or familymedical
history of the donor besides the standard information deliv-
ered by the histocompatibility center regarding infectious
agents and malign neoplasias.
The risk of transplanting an FAP patient with a TTR
V30Mpositive liver is admittedly low. However, in a country
that has performed more than a thousand of these transplant
procedures, such an event was to be expected, sooner or later.
DNA and serum-based assays for carrier status that could be
performed in a timely manner, while not standard, can be
easily implemented. It should be noted, though, that the legal
and ethical dimensions of performing what would possibly
be a predictive genetic test in a deceased donor is unchartered
territory, and would have to be addressed. Namely, the ques-
tion of whether it would be justified to communicate, in the
absence of consent, the genetic status of the deceased donor
to family members would have to be weighted in terms of
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possible benefits and harms. Nonetheless, as the whole point
of transplanting an FAP patient is to give her/him a wild type
TTR producing liver, screening of the donor should perhaps
be given serious consideration.
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Figure 1. MALDI-TOF-MS spectra of the serum samples of a liver
transplant donor (A), negative (B), and positive (C) controls.
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Inability of Mutant Transthyretin V30M to Cross the Blood-Eye Barrier
L iver transplantation is the main ther-apeutic option for familial amyloi-
dotic polyneuropathy (FAP) (Portuguese
type, caused by a substitution of methi-
onine for valine at position 30 of trans-
thyretin - TTRV30M) (1). It virtually
eliminates circulating TTR V30M, with
a positive impact on survival and qual-
ity of life (2). Domino liver transplan-
tation using grafts from FAP patients is
a well-established procedure (3) and is
regarded as a safe way to increase donor
availability (4, 5). However, reports of de
novo amyloidosis in FAP liver recipients
(6, 7) have caused much concern.
FAP patients present ophthalmic
disorders such as lacrimal dysfunction,
pupillary disturbances, glaucoma, and
vitreous opacities (8Y10). The ability of
mutant transthyretin to cross the blood-
brain (11) and blood-nerve barriers (6)
has been documented, but no conclusive
data exists about its ability to cross the
blood-eye barrier. If the circulating TTR
V30M penetrates the eye, the possibility of
acquired amyloidotic oculopathy should
be considered in FAP liver recipients.
CASE REPORT
A 63-year-old male, submitted
to domino liver transplantation be-
cause of hepatic alcoholic cirrhosis
2 years previously, underwent cataract
surgery. No previous ocular disease
was reported. At the beginning of sur-
gery, 0.1 mL of aqueous humor was
collected from the anterior chamber
and used for TTR V30M detection by
cyanogen bromide cleavage and sodi-
um dodecyl sulfateYpolyacrylamide gel
electrophoresis, as described by Saraiva
et al. (12), followed by Western blot
analysis with antiprealbumin primary
antibody (FL-147, #sc-13098; Santa
Cruz Biotechnology, CA). As positive
and negative controls, we used sera
from two individuals with a definite
diagnosis based on clinical findings and
the result of molecular testing for the
TTR V30M mutation. Cleavage of TTR
V30M with cyanogen bromide produces
an additional 10.6-kDa peptide frag-
ment because of the methionine residue
at position 30. This fragment was detected
in the serum of both the positive control
and the domino liver transplant recipient
(Fig. 1A,B). In the aqueous humor of the
domino liver transplant recipient, this
band was absent.
These results were complemen-
ted by matrix-assisted laser desorption/
ionizationYtime-of-flight mass spectro-
meter (MALDI TOF-MS) analysis, as
described by Haraoka et al. (13). Mass
spectra of TTR immunoprecipitated from
the aqueous humor and serum samples
were acquired in a 4800 MALDI-TOF/
TOF-MS (Applied Biosystems, Foster
City, CA) and were analyzed with Data
Explorer software version 4.9 (Applied
Biosystems). The spectra obtained are
represented in Figure 1CYF. Taking as
reference previously published results
(13), we can identify three peaks for
TTR in the positive control sample that
correspond to free and cysteine (Cys)-
conjugated forms of wild-type TTR
(13,776T10 d and 13,890T10 d) and Cys-
conjugated form of the TTR V30M
variant (13,923T10 d). In the negative
control sample we can see only the peaks
of the free and Cys conjugated forms
of wild-type TTR (13,766T10 d and
13,880T10 d). As in the negative control
sample, the spectrum of the aqueous
humor of the FAP liver transplant re-
cipient has the two peaks attributed
to wild-type TTR (13,761T10 d and
13,883T10 d), but the peak of mutant
TTR is absent. As expected, the mutant
TTR V30M peak was detected in this
patient’s serum (13,911T10 d).
DISCUSSION
Amyloid deposition has an impor-
tant role in oculopathy in FAP patients.
Therefore, determining the ability of mu-
tant TTR to cross the blood-eye barrier is
essential to predict the possible future oc-
currence of endocular pathology in FAP
donor domino liver recipients.
In this study, mutant TTR was not
detected in the aqueous humor of an
FAP liver recipient despite its presence in
the serum, suggesting that TTR and, in
particular, TTR V30M is unable to cross
the blood-eye barrier. Thus, the risk of
severe endocular disease seems to be
negligible in FAP liver recipients. Ocu-
lar manifestations associated with extra-
ocular amyloid deposition may still occur.
This study was carried out in a
liver transplant recipient with no known
previous eye disease. We do not know if,
in patients with existing or supervening
conditions, the integrity of the blood-
eye barrier is maintained.
It might be argued that small quan-
tities of variant TTR could be present in the
aqueous humor at a concentration below
the detection limits of both the Western
blotting and MALDI-TOF assays used.
However, even if that was the case, we
would like to point out that protein ag-
gregation and fibrillogenesis are highly
concentration-dependant phenomena and
that a threshold exists below which ag-
gregation is unlikely to occur (14, 15).
This work reinforces the current consen-
sus that domino liver transplantation
justifies the risks of iatrogenic FAP, al-
though careful monitoring of these pa-
tients will be necessary.
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FIGURE 1. Western blot after cyanogen bromide cleavage (A and B) and mass spectra (CYF); fragment (arrow) containing
the residues 30Y127 of the transthyretin with replacement at position 30 methionine for valine (TTR V30M) polypeptide
chain, present only in the carriers of the mutation. Lane P represents the positive control serum; N, the negative control
serum; T, the aqueous humor from the transplanted patient (A) and serum from the transplanted patient (B). Lanes M
represent the molecular weight marker used (MagicMark; Invitrogen, Carlsbad, CA). Mass spectra of a positive (C) and
negative (D) control serum for the TTR V30Mmutation and the aqueous humor (E) and serum sample (F) of the transplanted
patient. * Cysteine-conjugated form of wild-type TTR; 4 Cysteine-conjugated form of amyloydosis TTR V30M.
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New-Onset Parkinson Syndrome After Liver Transplantation
Serious neurologic complications (NCs)may occur in up to 45% of patients
after liver transplantation (LT). The
most common NCs were considered to
be encephalopathy and seizures in many
published series (1) and were associated
with increased morbidity and mortality
(2). It is often difficult to identify the cause
of the neurologic symptoms because of the
unspecific nature of their presentation.
NCs are frequently attributed to the
well-described adverse effects of calci-
neurin inhibitors, tacrolimus (TAC), or
cyclosporine A (3). The failure to rec-
ognize and adequately treat NCs can lead
to a fatal outcome (4).
In this case report, we describe a
manifestation of Parkinson syndrome
after LT.
A 47-year-old female underwent
deceased donor LT caused by alcohol-
related liver cirrhosis. The surgery was
uneventful. The immunosuppression ther-
apy was a calcineurin inhibitorYbased
triple regimen with TAC (with a target
level of 5Y8 ng/mL), mycophenolate
mofetil, and prednisone. The liver func-
tion tests were in the reference range
within 1 week. The patient was able to be
weaned from the ventilator 5 hr after
surgery. At this time, she was fully awake
and had good motor function. There
were no dopamine-blocking agents used.
On postoperative day (POD) 1,
the patient seemed somnolent. She fol-
lowed commands but was unable to
talk or move voluntarily. Slight rigor in
the patient’s extremities was also noted.
On the same day, the patient developed
akinesia, which significantly compro-
mised her respiratory function. In the
evening of POD 1, the patient was
reintubated. Her TAC blood level at
this time was 8.2 ng/mL. A computed
tomographic scan of the head did not
reveal any pathologic findings. On POD
2, the patient recovered completely and
was extubated. A neurologic consult
was performed, and no deficits were
found; however, 12 hr later, the patient’s
condition deteriorated significantly. The
patient developed the same clinical pic-
ture and had to be reintubated but
could be extubated few hours later. On
POD 3, the same clinical scenario re-
peated again. The neurologist was able
to see the patient before reintubation
and gave a diagnosis of an atypical Par-
kinson syndrome. Levodopa and ben-
serazide were administered. Soon after
treatment was started, the symptoms
resolved, and she finally maintained
respiratory stability. On POD 15, the
patient was discharged from the inten-
sive care unit. A follow-up magnetic
resonance imaging performed on POD
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